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Abstract

THE EFFECTS OF ISOCITRATE DEHYDROGENASE ON HUMAN MITOCHONDRIAL
EPIGENETICS
By John Andrew Strang, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.
Virginia Commonwealth University, 2014
Major Director: Dr. Shirley M. Taylor, Ph.D. Associate Professor of Microbiology and
Immunology
Aberrant metabolism has become an increasingly interesting area of cancer biology. In
many cancers including lower grade glioma, glioblastomas and some leukemias, a mutation in
the metabolic enzyme Isocitrate Dehydrogenase (IDH), has been found in more than 70% of
cases and has been shown to lead to a distinct hypermethylator phenotype. IDH commonly
converts isocitrate to alpha-ketoglutarate in normal cell metabolism. Three isoforms of this
enzyme are found in humans: IDH1, IDH2 and IDH3. Studies on IDH1, the cytosolic isoform,
have revealed that mutations in the enzyme’s binding site lead to a novel gain of function: the
synthesis of an oncogenic metabolite, 2-hydroxyglutarate (2HG). 2HG competitively inhibits
alpha-ketoglutarate dependent enzymes such as the TET 5-methylcytosine (5mC) oxygenases
and histone demethylases. These oxygenases are responsible for the hydroxymethylation (5hmC)
of cytosine residues, ultimately leading to demethylation and gene re-expression. Thus, mutant
IDH may lead to an elevation in 5mC levels producing the hypermethylator phenotype described.
A similar gain-of-function mutation in IDH2, the mitochondrial isoform of IDH1, has
been associated with leukemias and gliomas lacking IDH1 mutations. Mutations in IDH1, IDH2
and TET2 are mutually exclusive, and each yields a similar hypermethylator phenotype. IDH2,
x

along with IDH3, is primarily involved in the TCA cycle and energy production for the cell.
Recently, the Taylor lab has uncovered evidence of 5mC and 5hmC residues in mitochondrial
DNA, established and maintained by mtDNMT1 and TET2. Changing levels of mtDNMT1
appears to alter the patterns and levels of mtDNA transcription from the mitochondrial genome.
We hypothesized that mutant IDH would produce a similar effect on the mitochondrial genome
as that found in the nuclear genome and result in a decrease in the level of 5hydroxymethylcytosine, as well as a subsequent increase in the level of 5-methylcytosine caused
by the competitive inhibition of the TET enzymes by 2-hydroxyglutarate accumulation. Using
molecular biology techniques such as Western blots and MeDIP (methylated DNA
immunoprecipitation) I aim to uncover the role of IDH mutation on mitochondrial DNA
methylation and its effect on energy production in mammalian cells.

xi

Chapter 1: Introduction
The Study of Epigenetics in Cancer
Epigenetics is defined as the study of changes in gene expression independent of changes
in the DNA sequence itself (34). These genetic changes can be passed down from generation to
generation within a species and work to silence genes in a controlled and regulated way.
Mammalian species have evolved multiple regulatory pathways involving epigenetics including
the silencing of large portions of one of the X chromosomes in females during X linked
inactivation, differentiation of stem cells during development (28), and genomic imprinting.
Epigenetics can be subdivided into three major categories: Nucleosome remodeling, Histone
modifications and DNA methylation (88).
Of the three categories, DNA methylation is the most thoroughly studied. DNA
methylation involves the transfer of a methyl group from S-adenosylmethionine (SAM) to the
fifth carbon position of a cytosine residue in a cytosine guanosine (CpG) dinucleotide. There are
many CpG rich areas found in the genome called “CpG islands” which are defined as areas of
about 200 base pairs, containing an observed-to-expected CpG ratio of greater than 60%. These
CpG rich areas comprise about 40% of the promoters in mammalian genomes (35) with more
than 70% of human gene promoters carrying a large CpG content. Promoter CpG methylation in
mammals ultimately leads to the repression of transcription from that promoter (39). The
enzymes responsible for cytosine methylation in the human genome make up the family of DNA
methyltransferases (DNMTs). There are three catalytically active DNMT isoforms in the
mammalian genome that work to ensure that proper cytosine methylation occurs: DNMT1,
DNMT3a and DNMT3b. DNMT1 is known as a maintenance methyltransferase and works to

maintain the methylation patterns of the genome during DNA replication. Both DNMT3a and
DNMT3b work as de novo methyltransferases that place new methyl groups on cytosine residues
when necessary such as in early development (58, 88). A catalytically inactive DNA
methyltransferase, DNMT3L, also exists that establishes maternal genomic imprinting during
gametogenesis (9). Another DNA methyltransferase family member, originally labeled as
DNMT2, has been shown to mutilate the transfer RNA molecule that encodes for aspartic acid
and is therefore functionally distinct from the other DNMTs in that it can methylate RNA (23).
Over centuries, DNA methylation of the mammalian genome has lead to substantial CpG
dinucleotide depletion (27). Once methylated, cytosine residues can be deaminated
spontaneously or by activation-induced cytosine deaminase (AID) to thymine. Persistence of
thymine in place of cytosine results in CpG to TpG mutations, and a decrease in the total amount
of cytosine residues able to be methylated in the context of CpG dinucleotides. However, small
areas of the genome, typically found in the promoter areas of many genes have retained close to
the expected amount of CpG dinucleotides, largely because they are resistant to cytosine
methylation and these areas have been designated CpG islands. In normal differentiated cells, the
epigenome is generally described as unmethylated at these CpG island sites with concomitant
methylation of non-island CpG dinucleotides found usually within the body of the gene (Figure
1-1). These non-island CpG sites can also be found in repetitive areas within the genome as well
as around inserted viral sequences and transposons which can move to different areas of the
genome randomly. This pattern allows for ample gene transcription from the promoter start site
and represses unwanted transcription at these irregular elements of the cellular genome which
could do harm to the cell. In contrast to this pattern of normal gene transcription, in cancer the
epigenetics of the cell are altered to form an entirely different pattern of CpG methylation. A
2

Figure 1-1: Diagram representing differential patterns of methylation in normal and
cancerous cells. In normal cells, genes are characterized by hypomethylation at CpG island
promoter regions, which account for about 40% of gene promoter areas, and CpG methylation
within the gene body. Conversely, in cancer cells, the epigenomic pattern is marked by promoter
CpG island hypermethylation and a subsequent hypomethylation of CpG dinucleotides within
the gene body. Figure adapted from Herman, 2003, New England Journal of Medicine
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distinctive pattern is produced wherein the genome becomes globally hypomethylated with
subsequent hypermethylation of the CpG islands found at gene promoters (63). This pattern
generally leads to a large increase in gene transcription from normally repressed genes
(oncogenes) and an ensuing repression of gene transcription levels from normally active genes
(tumor suppressors). The genomic hypomethylation phenomenon can lead to greater genomic
instability and chromosomal rearrangement which in turn can lead to the uncontrolled activation
of growth promoting genes, such as RAS, and the loss of imprinting in many cells. This aberrant
growth has come to be known as one of the hallmarks of cancer (25). The abnormal methylation
pattern has become a field of intense study as epigenetic inactivation has succeeded mutational
inactivation as the most common insult found in the cancer genome. This hypermethylation is so
integral to the development of cancer that a distinctive phenotype, the CpG Island
Hypermethylator phenotype (CIMP), discovered in the 1990s, was confirmed by showing that a
subset of CpG islands is coordinately methylated in tumors (74). The subset of genes most
commonly affected in the CIMP phenotype are those that are targets for polycomb group
proteins which are essential for epigenetic silencing. Typically genes involved in cell cycle
progression, apoptosis, DNA repair and growth factor response, such as Rb, caspase 8, BRCA1
and ER respectively, are methylated so that the cell does not respond to arrest signals and
continues to grow leading to tumorigenesis (5 and 39). The rise in oncogenes that promote
growth and the fall in tumor suppressing genes that inhibit expansion both work to define cancer
in many tumor types.
Many studies have pointed to the DNA methyltransferase, DNMT1, the maintenance
methyltransferase, as the culprit of abnormal methylation patterns during tumorigenesis (27).
This enzyme methylates newly synthesized hemimethylated daughter strands after replication to
4

ensure stably inherited methylation of the genome from generation to generation. However, this
enzyme interacts with the other DNMTs, the de novo methyltransferases DNMT3A and
DNMT3B, to establish patterns of methylation and all three are required for normal embryonic
development, making a single cause of aberrant methylation in cancer difficult to pinpoint. Other
studies have shown that DNMTs work with histones and the chromatin surrounding CpG island
promoters to activate and repress gene transcription. In normal cells, where promoters are
unmethylated at CpG sites, nucleosomes are widely spaced. This spacing is achieved by histone
tail modifications, such as acetylation of key lysine residues on histone H3, which open up the
nucleosomes allowing access by transcription factors to the promoter for gene transcription
activation. Contrasting this, in cancer where CpG island promoter regions are almost exclusively
methylated, the nucleosomes are condensed prohibiting transcription factors from binding to the
promoter region of this gene. These regions are also typically associated with histone
deacetylases and histone methylation marks at lysine 9 of histone H3 which are typically
indicative of gene repression and inactivation (27). The study of epigenetics is critical to
understanding tumorigenesis and many connections between histone modifications, nucleosome
remodeling and cytosine methylation have been made in regards to gene transcription regulation.
It is now impossible to think of cancer without understanding epigenetic processes as well. In
this thesis, we have focused on cytosine modifications and the relationship they play in
transcription to alter gene expression as it relates to reprogramming metabolism.
The Role of Isocitrate Dehydrogenase in the Tricarboxylic Acid Cycle
Multiple enzymes of the TCA cycle have been shown to be implicated in the progression
of cancer including Succinate Dehydrogenase (SDH) (67) and Fumarate Hydratase (FH) (31).
These enzymes, in normal tissues, typically contribute to ATP production
5

via the TCA cycle and once mutated, such as in cancer, lead to the accumulation of metabolic
intermediates within the cell and aberrant cellular metabolism. This build up leads to an increase
in the production of hypoxia inducible factor α (HIFα) which works to facilitate the cell’s
response to a hypoxic environment. This response contributes to the processes of angiogenesis,
apoptosis and metabolism so that the cell can survive in a low-oxygen situation. With HIF1α
constitutively expressed in cancer cells, they can continue to survive even with little oxygen,
contributing to the Warburg effect (38). Another metabolite of interest to the scientific
community as it relates to cancer biology is the enzyme Isocitrate Dehydrogenase or IDH.
IDH is an enzyme of the TCA cycle (Figure 1-2) that catalyzes the oxidative
decarboxylation of isocitrate to the metabolite α-ketoglutarate which, due to the high change in
negative free energy associated with this reaction, has been termed an irreversible step of the
TCA cycle and is very tightly regulated (2). Three different isoforms of this enzyme exist: IDH1,
IDH2 and IDH3 which are all encoded by separate genes found in the nucleus. IDH3 is
composed of two alpha chains, one beta chain and one gamma chain while both IDH1 and IDH2
are homodimers (70). While all three isoforms catalyze the same reaction, IDH1 and IDH2 are
able to reverse this process if need be and help to regulate the amount of α-ketoglutarate and
NADPH pools produced within the cell (47). The isoforms are localized to different subcellular
compartments in the cell, with both IDH2 and IDH3 contained in the mitochondria while IDH1
is found in the cytosol and in peroxisomes. Both IDH1 and IDH2 utilize the electron acceptor
NADP+ while IDH3 uses NAD+ as an electron acceptor to generate NADPH and NADH
respectively. This reaction requires the use of a Mn2+ ion found in the active site of the enzyme
which helps to stabilize the isocitrate molecule as it is converted to α-ketoglutarate through a
highly unstable enol intermediate (Lehninger, 2008). This reaction utilizes a molecule of
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NAD(P)+ which oxidizes a hydride transfer to create one molecule of NAD(P)H which can be
used in the oxidative phosphorylation pathway found in the mitochondria. This oxidation of
isocitrate creates the oxalosuccinate intermediate which remains in the active site of the enzyme
where one molecule of CO2 is released. With the help of the Mn2+ ion, the enol intermediate is
stabilized and converted into α-KG which can be used elsewhere in the cell. α-KG is an essential
molecule of the TCA cycle and is required for many enzymes in relation to metabolism including
those needed for amino acid synthesis, nitrogen transport, collagen formation and oxidation
reactions among others. Of particularly interesting importance is the fact that α-KG is integral to
many enzymes including a family of dioxygenases called the Ten Eleven Translocation (TET)
family. The effect this enzyme has on the cell is quite intriguing and was examined in this thesis
to discern if the alterations caused by IDH reached into the mitochondrial genome where cellular
metabolism is regulated.
The Role of Isocitrate Dehydrogenase in Gene Expression and Cellular Differentiation
The TET family of dioxygenases is composed of three isoforms: TET1, TET2, and TET3
which utilize α-ketoglutarate, as well as Fe2+ and O2 to catalyze the conversion of 5methylcytosine to a novel base, 5-hydroxymethylcytosine (32). Little is known about this new
DNA modification although recent research points to its possible role in DNA demethylation and
ultimately gene re-expression (Lu and Thompson, 2012 and 24). The TET enzymes initially
oxidize the 5-methylcytosine base to 5-hydroxymethylcytosine and further oxidize this alteration
to 5-formylcytosine and finally 5-carboxylcytosine where it is rapidly removed from the cell by
the enzyme Thymine DNA Glycosylase (TDG) (33,26). The TDG enzyme recognizes the 5caC
residue as a mismatch to the usual guanosine and replaces the modified cytosine with a newly
unmodified cytosine residue via the base excision repair machinery. It is through this mechanism
7

Figure 1-2: The Tricarboxylic Acid Cycle. Enzymes are boxed in hexagonal shapes while
products of enzymatic reactions appear in colored ovals. By-products of each reaction are also
displayed.
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that DNA demethylation is possible which ultimately leads to the re-expression of genes that
were silenced by methylation of the cytosine residues (85). Reports have uncovered that more
than 70% of grade II and grade III gliomas, most secondary glioblastomas and even some
instances of acute myeloid leukemia contain a somatic point mutation in the IDH1 or IDH2
genes (87, 50), and this has been shown to lead to the distinctive CpG island methylator
phenotype (CIMP) which is characterized by a global hypermethylation of the genome and
defines a distinctive subgroup of gliomas (56). Patients known to contain the CIMP phenotype
have been diagnosed earlier on in age and usually present with a more favorable prognosis than
CIMP negative patients (12 and 52). In 2012, research discovered that, not only are the IDH
mutation and the CIMP phenotype connected, but IDH1 mutation is sufficient to establish this
hypermethylator phenotype in the genome of many glioma samples by disrupting DNA and
histone methylation patterns produced in the nucleus (76). This mutation occurs at analogous
arginine residues found in the active site of the enzymes and is a defining feature of tumor
progression (4). One mutation, R132H is found in the IDH1 isoform while the IDH2 isoform
most commonly contracts the R140Q or R172K mutation in these cancerous instances. Once
originally thought to lead to a loss of IDH function, these mutations result in the loss of stability
of the β-carboxyl of the isocitrate metabolite which is docked in the enzyme (82). Studies
investigating both IDH1, the cytosolic isoform, and IDH2, the mitochondrial isoform, have
revealed these mutations are heterozygous and that one wild-type allele is typically maintained
(15, 82). This heterozygosity was predicted to confer a novel gain of function on these enzymes,
and a neomorphic activity was demonstrated (15) leading to the synthesis of a new metabolite, 2hydroxyglutarate (2-HG), an analog of α-ketoglutarate. 2-HG contains a hydroxyl group at the
carbon 2 position whereas the carbon 2 position of α-ketoglutarate has an oxygen molecule
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bound to it. The D (-) enantiomer of 2-HG is typically produced via the IDH mutation. It is
believed that while the wild-type allele of IDH is used to convert isocitrate into α-ketoglutarate,
the mutant allele can use the newly synthesized metabolite, as well as NADPH, to reduce it to 2HG and create a molecule of NADP+ in the process. This new molecule, 2-HG, which is
commonly kept at low levels below 0.1nM (47), builds up substantially within the cell and
consequently reduces the pool of α-ketoglutarate available. Researchers have shown that the
metabolite 2-HG competitively inhibits the active sites of enzymes, such as the TET
dioxygenases mentioned above (86). This inhibition of the TET enzymes leads to a decrease in
the amount of 5-hydroxymethylcytosine produced and a subsequent rise in 5-methylcytosine
residues in the nuclear DNA of the cell which establishes a hypermethylator phenotype such as
that described (76). Of particular note is the distribution of IDH mutations in cancer. In acute
myeloid leukemia (AML), the IDH1 and IDH2 mutations are mutually exclusive to each other as
well as to TET2 mutations commonly found in myeloid cancers (1, 41,16), confirming the
hypothesis that these mutations have a similar mechanism of action to disrupt the methylation
patterns of the cell (21). Along with the inhibition of TET enzymes, other α-ketoglutarate
dependent enzymes are affected by this mutation including histone modifying enzymes which
control cellular differentiation and gene expression. Experiments performed in this thesis were
aimed at more fully understanding the far-reaching effects of mutant IDH.
The Human Mitochondrion and its Role
The circular double stranded mitochondrial genome is approximately 16.6 kilobases in length in
humans and roughly 16.3 kilobases in mice (Figure 1-3). Each cell contains anywhere from 100
to 10000 copies of mitochondrial DNA (20) and these mitochondrial genomes lack introns. Each
strand, designated as either the heavy strand (guanosine rich) or light strand (guanosine poor),
10

encodes 28 and 9 genes respectively which, when combined, account for 13 protein coding
genes, 22 transfer RNAs and two ribosomal RNAs. The 13 open reading frames produce 13
proteins that are integral components of four of the five oxidative phosphorylation complexes
necessary for energy production in the cell (79). The mitochondrial genome also contains a
control region termed the D-loop where an origin of replication can be found as well as three
separate transcriptional promoters. These three promoters each transcribe a specific polycistronic
message from the mitochondrial genome. Heavy strand promoter 1 (HSP1) produces a message
that encodes the two rRNAs, which are designated as 12S and 16S, and terminates at the end of
the 16S gene. This termination process is dependent upon the mitochondrial transcription
termination factor (mTERF) which creates a loop between the HSP1 promoter and the end of the
16S gene to control the level of H1 transcript present in the cell (51). HSP2 is close to the 5’ end
of the 12s rRNA gene and encodes the entire heavy strand. The light strand promoter (LSP)
allows for the transcription and translation of the entire light strand of the mitochondrial genome.
mtDNA transcription is initiated by the mitochondrial transcription factor A (TFAM), as well as
many other factors, which work to unwind the DNA and allow for promoter recognition by the
mitochondrial RNA polymerase (POLRMT) so that transcription can begin. Interestingly,
mtDNA transcription functions independently of nuclear genomic transcription and can be
initiated at different times in each mitochondrion found in the cell without any phase specificity
meaning that not every mitochondrion is producing the same message at the same time (20). It is
possible that this allows for greater production of necessary mitochondrial components when
necessary in the cell.
Evidence suggests that mitochondria play an integral role in many disease states
including Diabetes, Alzheimer’s, Parkinson’s disease and cancer, which has led many research
11

Figure 1-3: Organization of the mitochondrial genome in human cells. All genes encoded on
this genome are shown as well as the start sites for the three different transcription products. The
heavy strand is denoted in blue, the light strand denoted in black and the tRNA genes are denoted
in red.
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laboratories to investigate the effects of mitochondrial function and regulation in these illnesses
(45, 66). Mitochondrial DNA is predominantly inherited via maternal inheritance in mammals
although rare cases of paternal inheritance have been reported (Shapira, 2006). Most
mitochondria in a cell contain the same genetic code, which is termed homoplasmy. However,
due to the large volume of mitochondria in the cell and the generation of free oxygen radicals
produced by the respiratory chain itself, mutations can arise much more frequently than in the
nuclear genome. Also, during replication, different numbers of mitochondria can segregate into
the new daughter cells produced. The coexistence of mutant and wild-type mtDNA is called
heteroplasmy, and mutations accumulate as the individual organism ages (Shapira, 2006).
Mitochondrial mutations commonly take the form of either a deletion or random point mutations.
Many different mtDNA mutations have been characterized and result in debilitating pathologies
(42). Not only are mtDNA mutations important in disease states, but mutations can also occur in
the nuclear DNA that encodes mitochondrial proteins. Indeed, in Alzheimer’s disease, the gene
encoding the amyloid precursor protein is mutated which leads to the impairment of oxidative
phosphorylation processes in the cell as well as severe accumulation of senile plaques, a
common attribute of this disease (Lin, 2006). Transcription of mitochondrially encoded peptides,
such as the ND6 and ND2 genes on the mitochondrial light and heavy strands respectively, have
also been shown to be reduced by 50% in the brains of many Alzheimer’s patients suggesting an
effect on mitochondrial gene transcription (79).
Evidence also suggests that change in mitochondrial function contribute to the ageing
process (14). As an organism ages, electron transport chain function declines leading to a
subsequent increase in the production of reactive oxygen species (71). These changes seem to be
brought on by the increasing levels of mutations found in the mitochondrial DNA over time as
13

oxidative phosphorylation processes are continuously being employed. The generation of ROS
inside the cell leads to the activation of the mitochondrial permeability transition pore (mtPTP)
which in turn increases the likelihood of apoptosis by releasing the contents of the mitochondria
into the cellular cytosol, including the apoptotic promoting molecule, cytochrome c (77 and 79).
Cellular ageing results in the decreased activity of mitochondrial encoded proteins such as those
found in Complex I and Complex IV of the electron transport chain (71). These studies confirm
the critical importance of the mitochondrial genome in cellular homeostasis. With this
knowledge, this thesis aims to uncover how a mutant enzyme, IDH, can alter mitochondrial
transcription and thereby alter this organelle’s function.
The Warburg Hypothesis
In the 1920s, Dr. Otto Warburg hypothesized that cancer is a disease of metabolism and
can be interpreted as a disease of mitochondrial misregulation (Presner, 2011). Specifically,
Warburg proposed that in cancer, there is a general shift in how cells acquire nutrients, generate
energy and regulate their metabolism (Figure 1-4). In the presence of oxygen, most nonproliferating undifferentiated cells use the mitochondrial tricarboxylic acid (TCA) cycle to
metabolize glucose into carbon dioxide by oxidative phosphorylation (83). Through multiple
enzymatic conversions and phosphorylations, glucose is broken down into two molecules of
pyruvate, a three carbon chain, in the cytoplasm during glycolysis. These pyruvate molecules are
then shuttled through the mitochondrial membrane and converted to acetyl-coA molecules where
they undergo oxidation to create adenosine triphosphates. Once inside the matrix of the
mitochondrion, one molecule of acetyl-coA is metabolized to ultimately produce three molecules
of NADH, one molecule of FADH2, one molecule of GTP or ATP and two molecules of CO2.
The CO2 molecules are taken out of the cell and exhaled out of the body. The GTP/ATP
14

Figure 1-4: The Warburg effect. Comparing the difference in energy usage between
differentiated tissues and proliferative or tumor tissues. The production of lactate is favored over
oxidative phosphorylation in tumor samples whether in the presence or absence of oxygen.
Figure adapted from Vander Heiden, 2009.
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molecule generated can be used as a fuel source and energy producer. The NADH and FADH2
molecules produced by the TCA cycle help to shuttle electrons through the mitochondrial inner
membrane to O2 molecules via oxidative phosphorylation. Through OXPHOS, H+ ions are
subsequently pushed into the intermembrane space to create a gradient of charge across the
membrane. This gradient helps to provide the necessary energy to synthesize ATP from ADP
and inorganic phosphate using the ATP synthase enzyme, which ultimately leads to the
production of about 15 molecules of ATP which, when calculated, totals to about 32 molecules
of ATP generated per molecule of glucose taken up in the diet (55). This vast amount of ATP is
used as energy in the cell to do work and catabolize necessary materials.
In an environment where oxygen is in short supply, such as during strenuous exercise,
mammalian cells will undergo glycolysis for quick ATP production. This process utilizes a
glucose molecule to produce two molecules of pyruvate which are then reduced into a total of
two molecules of lactate. Lactate can be used within the cell to generate two net molecules of
ATP for energy. This production of ATP through glycolysis is much smaller than the amount of
energy produced during oxidative phosphorylation and requires much more glucose to produce
the same effect as the relatively small number of glucose molecules needed during aerobic
conditions (46). Cancerous cells on the other hand, as observed by Warburg, tend to consume
extremely large amounts of glucose and produce abnormally high levels of lactate even in the
presence of ample supplies of oxygen (38). This process, termed aerobic glycolysis, has become
a defining feature of most cancers of the human body. Today, Otto Warburg’s hypothesis from
more than 80 years ago has garnered much attention, as aberrant metabolism has evolved as
another hallmark of cancer biology. In this present work, we aim to uncover how metabolism can
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be altered by studying the mitochondrial genome and how the effects produced by a mutant
enzyme can lead to dysregulation in this system.
The Study of Epigenetics as it Pertains to the Mitochondria
Early studies uncovered the existence of 5-methylcytosine residues in the human
mitochondrial genome as well as in many other species including rat, hamster, mouse and cow.
However, this idea of mitochondrial epigenetics has remained somewhat controversial over the
past few years. Earlier reports point to the fact that mitochondrial DNA contains no histones and
instead bundles its content into nucleoids tethered to the mitochondrial inner membrane by the
protein TFAM (Transcription Factor A) along with other proteins necessary in mitochondrial
maintenance (22). Also, there was no evidence to suggest that methylases can enter the
mitochondria in mammals. The Taylor lab has addressed these problems and put this debate to
rest once and for all. Recent evidence suggests that earlier assessments of the possibility of
mitochondrial epigenetics may have been incorrect. DNMT1 has been shown to be able to enter
the mitochondrial genome using an upstream start site in translation that encodes an N-terminal
mitochondrial leader sequence, allowing mtDNMT1 to enter the mitochondria and methylate
cytosine residues in the mitochondrial genome (68). The two de novo methyltransferases,
DNMT3a (11) and DNMT3b (6), have also been suggested to enter the mitochondria, although
this evidence is not as strong. While not much is known about this new mitochondrial DNA
modification or its function, evidence has found that 5-methylcytosine preferentially exists at
non-CpG dinucleotide sites as opposed to CpG dinucleotides which are more commonly found in
nuclear DNA methylation patterns (Belizzi, 2013). The Taylor lab was also able to uncover the
existence of 5-hydroxymethylcytosine residues in the mitochondrial genome; while the presence
of this modification in the mitochondrial genome remains to be determined, levels in mouse
17

Figure 1-5: p53 status affects mitochondrial gene expression in a gene-specific manner. p53
affects expression level of the mitochondrial isoform of DNMT1 which can lead to an effect on
gene expression of the protein-coding genes of the mitochondria. Levels of mRNA for ND1 and
ND6 were differentially expressed after loss of p53. Adapted from Shock, 2011.
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brain mitochondria have been implicated in the aging process (18). Also of note, cytosine
modifications in the mitochondrial genome have a gene-specific effect on the protein-coding
genes as ND6 (the protein encoded on the light strand) is downregulated while ND1 (the first
protein-coding gene after the ribosomal RNA genes) is upregulated in p53-null cells which
transcribe an abundance of mtDNMT1 mRNA (Figure 1-5 adapted from 68).With this finding,
research has been performed to determine that the TET enzymes, as well as DNMTs, can cross
into the mitochondria and perform their enzymatic functions on mtDNA (6). It stands to reason
that while not much is known about mitochondrial epigenetics, mitochondrial methylation and its
subsequent hydroxymethylation may have a serious effect on oxidative phosphorylation and
energy production in the cell through their effects on gene transcription of the mitochondrial
genome.
As mitochondrial dysfunction and metabolic reprogramming seem to play an important
role in many disease states including cancer, it seems logical that mutant IDH protein would
have a significant effect on mitochondrial epigenetic levels. Previous studies have identified the
effect IDH mutation has on nuclear epigenetics as well as histone modifications to control gene
expression and cellular differentiation respectively, but studies on a possible mitochondrial effect
have been lacking at this time. We propose that IDH mutation would affect the levels 5hydroxymethylcytosine residues found in the mitochondrial genome via production of 2hydroxyglutarate which will lead to the inhibition of TET enzymes located within the
mitochondria. A fall in 5-hydroxymethylcytosine content could lead to the establishment of a
hypermethylator phenotype in the mitochondria as previously shown in the nuclear genome. To
determine if any effects on mitochondrial epigenetics result when IDH mutations are introduced,
an innovative technique, Methylated DNA Immunoprecipitation (MeDIP), will be used to
19

quantitate the 5mC and 5hmC residues found in the mitochondrial genome, as traditional
Bisulfite sequencing cannot distinguish between these two modified bases (29). Quantitative
polymerase chain reaction will be used to quantitatively determine how the levels of 5mC and
5hmC are affected in the mitochondrial genome, specifically the regions encoding the 12S and
16S rRNA genes.
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Chapter 2: Materials and Methods
Cells, Cell culture, and plasmids used to determine the effect of IDH mutations on
mitochondria
The cDNAs encoding IDH1, IDH2, L2HGDH or D2HGDH were obtained from the
Arizona State University DNA repository and recloned into either pDEST26 C-FLAG (IDH) or
pcDNA 6.2/myc (HGDH). Site directed mutagenesis was carried out using the Quick-Change
Mutagenesis kit from Agilent to generate the IDH1 R132H and IDH2 R172K mutations. All
cloning and mutagenesis was carried out by the Biological Macromolecule Core Laboratory at
Virginia Commonwealth University. All plasmids were verified by DNA sequence analysis.
Both HEK293 and HCT-116 cell lines were used in this project. Cells were grown in either 6well plates (for protein extracts) or 100mm dishes (for DNA purification) in DMEM media with
10% Fetal Bovine Serum (Atlanta) in 10% CO2 in a humidified incubator at 37⁰C.
Transient transfection
Once cells reached 70-80% confluency in their respective dishes, transient transfections
were performed. Plasmids encoding epitope-tagged proteins are shown in Table 1. For 6-well
plates, 2µg of each plasmid was diluted with 50uL of serum free DMEM media (high glucose)
and 6µL Polyjet Transfection reagent (SignaGen Laboratories Cat #SL100688) was also diluted
with 50µL serum free DMEM and added to diluted plasmid. After 15 minutes at room
temperature, each transfection mixture was pipetted into a well containing 70-80% confluent
cells. The cells were incubated overnight and the next day fed with DMEM media containing
10% FBS and 1% Penicillin-Streptomycin. Media was replaced 24 hours post-transfection and,
after 48 hours, cells were harvested. Cells were washed twice with cold non-sterile PBS
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Table 1: Table of expression plasmids used in this thesis. Antibobies needed for
immunoblotting as well as antibiotics necessary for generation of stables is provided.
Sample
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Plasmid 1
IDH1 wild-type
IDH1 wild-type
IDH1 wild-type
IDH1 mutant
IDH1 mutant
IDH1 mutant
IDH2 wild-type
IDH2 wild-type
IDH2 wild-type
IDH2 mutant
IDH2 mutant
IDH2 mutant
L2HGDH
D2HGDH
pIRES neo2
pcDNA3.1
myc/hisB
Untransfected
pMAX GFP

Plasmid 2
L2HGDH
D2HGDH
L2HGDH
D2HGDH
L2HGDH
D2HGDH
L2HGDH
D2HGDH

Western Blot Antibody
Needed
FLAG
FLAG/Myc
FLAG/Myc
FLAG
FLAG/Myc
FLAG/Myc
FLAG
FLAG/Myc
FLAG/Myc
FLAG
FLAG/Myc
FLAG/Myc
Myc
Myc

Drug Selection for Stables
Neomycin
Neomycin/Blasticidin
Neomycin/Blasticidin
Neomycin
Neomycin/Blasticidin
Neomycin/Blasticidin
Neomycin
Neomycin/Blasticidin
Neomycin/Blasticidin
Neomycin
Neomycin/Blasticidin
Neomycin/Blasticidin
Blasticidin
Blasticidin
Neomycin
Blasticidin
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(pH 7.4), scraped from dish and collected by centrifugation in pre-weighed 1.5mL centrifuge
tubes. Media was removed and cold non-sterile PBS (pH 7.4) was used to wash each well twice.
Cells were resuspended in 5µL/mg wet weight in SDS lysis buffer (2.25 mL EDTA free protease
inhibitor tablets (Roche) resuspended in 2X sample buffer (62.5 mM Tris-HCl, pH 7.5, 5%
glycerol, 2% SDS), 2.025mL water, 225 µL β-Mercaptoethanol) and sonicated on high power
for 7.5 minutes at 30 seconds on, 30 seconds off intervals in a Diagenode Bioruptor bath
sonicator and stored at -80⁰C for use in immunoblotting.
Samples for DNA extraction were transfected in 100mm dishes using 8µg of each
plasmid, 20µL of Polyjet Transfection reagent and 150µL of serum free DMEM as diluents as
described above for 6-well plates. After 15 minutes at room temperature, each transfection
mixture was pipetted onto a plate containing 70-80% confluent cells. As previously described,
media was replaced 24 hours post-transfection and at 48 hours post-transfection, cells were
scraped into 1.5mL centrifuge tubes, pelleted and stored at -80⁰C for later DNA extraction.
Selection of Stable Transfectants
To create cell lines that stably express the plasmids of interest, either 100mm
(Blasticidin resistance plasmids) or 150mm dishes (Neomycin resistance plasmids) were used.
Cells were brought to 70-80% confluence and transfections were performed as described for
transient transfections, above. For 150mm dishes, 300uL of serum free DMEM media, 12ug of
each plasmid DNA and 30uL of polyjet reagent were used. Stable integration of plasmid was
selected using neomycin (1mg/mL), blasticidin (2µg/mL) or both drugs together, as indicated in
Table 1. An untransfected control was also used to ensure that plasmids were integrated into the
cellular genome. Once colonies began to form on the dishes, 12 were removed using sterile
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polyester Q-tips and placed in one well of a 12-well plate. Media was replaced with designated
drug until colonies reached confluency in their wells. The cells were then trypsinized from their
wells, pelleted and aliquoted into 100mm dishes (DNA isolation), 60mm dishes (protein
extraction and immunoblot) or individual wells of a 24 well plate for cryopreservation, using
freezing media (90% FBS, 10% DMSO). 300µL of total cells were plated for freezing, while 1/3
total volume of cells were aliquoted into 60mm dishes and the remaining cells were aliquoted
into 100mm dishes.
Protein Concentration Assays
The Bradford Assay was used to determine protein concentration of each sample that was
harvested from either 6-well plates (transient transfection) or 60mm dishes (stable transfection).
Duplicate assays were conducted for each sample as well as for the standard curve. Standard
curve samples contained 699-799µL of H2O at 20µL intervals, 1µL of SDS lysis buffer and BSA
(0-10µg) while sample tubes contained 799µL of H2O and 1µL of protein extract. 200µL of
BioRad dye concentrate (Cat # 500-0006) was added to each tube. After a 15 minute incubation
at room temperature, absorbance was determined using a spectrophotometer at 595nm
wavelength.
Immunoblot Assays of Protein Expression
Each sample (40µg) was mixed with an equal volume of Laemmli Sample Buffer
(475uL Laemmli Buffer (Cat# 161-0737)/25uL of β-mercaptoethanol), and total volume was
adjusted to 37µL with SDS lysis buffer. Samples were run alongside Precision plus Dual Color
protein ladder (Biorad Cat# 1610374) in 1X Running Buffer (25mM Tris, 250mM glycine, 0.1%

24

Table 2: List of antibodies used for western blotting
Expected
Primary Ab

Primary

obtained

Ab

from

Dilution

Secondary
Blocking Secondary

Antigen

protein

Chemiluminescent

band

substrate prepared

Ab
Buffer

Ab Used
Dilution

size
Sigma

Goat
Starting

FLAG

Aldrich

1:500

Anti-

1:15000

50 kD

½ Dura

1:10000

50 kD

Full Pico

1:1000

50 kD

¼ Dura

1:3000

32 kD

Full Pico

1:5000

18 kD

Full Pico

Block
Cat. F1804

Mouse

Invitrogen

Goat
Starting

Myc

Cat. R950-

1:2000

AntiBlock
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Rabbit

Cell

Goat
Starting

IDH

Signaling

1:1000

AntiBlock

Cat. 12652

Rabbit

Cell
Goat
Signaling
VDAC

Starting
1:2500

Technology

AntiBlock
Rabbit

Cat. 4661
Goat
Millipore
Cyclophilin A

Starting
1:5000

Cat. 07-313

AntiBlock
Rabbit
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SDS). Samples were boiled for 10minutes. Proteins were resolved on a 10% polyacrylamide gel
for one hour at 150 volts. Gel was washed in water then transferred to a PVDF membrane
(Millipore, Cat# IPVH0010) that was pre-washed in 100% Methanol. Transfer was performed in
ice bath with stir bar placed in transfer apparatus for 50 minutes at 100 volts in 1X Transfer
Buffer (25mM Tris-HCl, pH 8.3, 192mM glycine, 10% Methanol and 0.04% SDS), and
membranes were incubated in Starting Block buffer (Thermo Scientific) overnight at 4oC.
Membranes were washed in 1X TBS-T (25mM Tris-HCl, pH 8.3, 192mM glycine, 0.04% SDS,
0.1% Tween-20) for 5 minutes and exposed to epitope-specific primary antibodies for one hour.
All primary and secondary antibodies, as well as dilutions used, are listed in Table 2. VDAC or
Cyclophilin A was used as a loading control. After one hour incubation, membranes were
washed in 1X TBS-T thrice for 5 minutes and then incubated with secondary antibody for one
hour (using antibodies specific for Fc regions of primary antibodies). After incubation, three 10
minute washes in 1X TBS-T were performed. During this time, chemiluminescent substrates
were prepared using either West Dura (Pierce, Cat# 34075) or West Pico (Pierce, Cat# 34080).
Once washed, membranes were dried, incubated in substrates for 3 minutes, wrapped in saran
wrap and exposed on film to determine protein expression levels.
Purification of DNA from transfected cell lines
Once protein expression levels had been determined, cell pellets from 100mm dishes for
DNA extraction were lysed using the DNeasy Blood and Tissue Kit from Qiagen (Cat# 69504),
following the manufacturer’s protocol. An RNase treatment was used to ensure pure DNA was
collected and any RNA was destroyed in each sample, since RNA can also be modified at
cytosine residues. The DNA was further purified to destroy any remaining RNA by incubating
with 0.5M NaOH at 37⁰C overnight in a water bath. DNA was recovered following phenol26

chloroform extraction by ethanol precipitation. Extracted DNA was resuspended in 200uL of AE
buffer (Qiagen) and concentration was measured on the NanoDrop spectrophotometer to
determine DNA concentration. With this purified DNA, samples were sonicated twice at high
power for 15 minutes using intervals of 30 seconds on, 30 seconds off to obtain DNA fragments
between 200-700bp. This sonicated DNA was resolved on a 1.5% agarose gel for 70 minutes at
100 volts to verify the correct fragment size of DNA needed for MeDIP experiments.
MeDIP/Hydroxy-MeDIP Assay
Once DNA of correct length and purity was obtained, MeDIP was performed to obtain
methylated and hydroxymethylated DNA of sample (visual of MeDIP displayed in Figure 2-1).
As the 5-methylcytosine and 5-hydroxymethylcytosine antibodies were produced in mouse and
rabbit species respectively, both an IgG mouse and IgG rabbit antibody were necessary as
measures of baseline in this experiment. 4ug of purified and sonicated DNA was brought up in
Tris EDTA buffer (10mM Tris, 1mM EDTA) to 450uL total volume. This procedure was
repeated to generate 4 tubes of 4µg for each DNA sample used in MeDIP experiment. These
tubes were subjected to denaturation by submerging in boiling water for 10 minutes and then
immediately placed on ice for 10 minutes. After denaturation, samples were mixed with 51uL of
10X IP buffer (100mM Na-Phosphate pH 7.0, 1.4M NaCl, 0.5% Triton X-100) and rotated endover-end at 4⁰C overnight with 2µg of one specific antibody for each tube which include: IgG
rabbit monoclonal control (Santa Cruz Biotechnologies, Cat# SC-2027), IgG mouse polyclonal
control (Millipore, Cat# 12-371), 5-methylcytidine antibody (Epigenetek, Cat# A-1014) or 5hydroxymethylcytidine antibody (Active Motif, Cat# 39769). To ensure proper capture of 5methyl and 5-hydroxymethyl residues, IgG protein beads were pre-blocked prior to use in
immunoprecipitation the following day. Beads were washed three times in 0.1% PBS-BSA
27

Figure 2-1: Schematic representing the protocol used for the MeDIP/Hydroxy-MeDIP
method. Protocol followed to ensure adequate isolation of methylated/hydroxymethylated DNA
residues respectively.
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(10mg of BSA were dissolved in 9mL of 1X PBS pH7.4 and 1mL of H2O), each time being
rotated end-over-end at 4⁰C for 5 minutes and pelleted at 4500rpm for 5 minutes at 4⁰C. These
beads were resuspended in an equivalent volume of 1X IP buffer and blocked using 5µg/30µL
IgG bead slurry BSA and 5µg/30µL IgG bead slurry sonicated Lambda DNA. Beads were
rotated at 4⁰C for three hour incubation. Afterwards, beads were washed three more times with
0.1% PBS-BSA, rotated and pelleted as before. 50% IgG bead-1X IP slurry was prepared again
and 20µL of slurry was aliquoted into each sample to capture antibodies that adhered to DNA
regions of interest and rotated with beads for 2 hours at 4⁰C. After incubation, beads were
pelleted and supernatants of IgG control samples were saved for later use as input samples for
quantitative PCR. Beads of all samples were then washed with 500µL 1X IP solution, rotated
end-over-end for 10 minutes and pelleted at 4500rpm for 2 minutes at 4⁰C three times. After
pelleting beads for the third time, samples were resuspended in 250µL Proteinase K digestion
buffer (50mM Tris pH 8.0, 10mM EDTA, 0.5% SDS) and 3.5µL of Proteinase K (20mg/mL)
was added to each sample and tubes were left to incubate for 3 hours at 50⁰C in a rotating water
bath. Samples, including saved supernatants from IgG controls, were then extracted with of
25:24:1 phenol:chloroform:isoamyl alcohol (250µL), spun at 13200rpm for 5 minutes at 4⁰C and
the aqueous layer containing DNA was removed. Samples were then extracted with and an
equivalent volume of chloroform (250µL), and spun again at 13200rpm for 5 minutes at 4⁰C.
The top aqueous layer was collected and precipitated with 1/10th the volume of 3M sodium
acetate (25µL), glycogen (4µL) and 100% ethanol (750µL) to recover immunoprecipitated DNA.
Samples were left to precipitate overnight at -80⁰C. The following day, samples were spun at
13200rpm for 20 minutes at 4⁰C to pellet DNA. Supernatant was removed and 70% Ethanol
(500µL) was dispensed into each sample and spun again at 13200rpm for 10 minutes at 4⁰C.
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Supernatant was removed from pelleted DNA and samples were dried for 10 minutes,
resuspended in 75µL TE buffer and stored at -20⁰C for later use. For the experiment using
HCT116 cells, the supernatants of each IgG control were not collected and the material that
bound to the beads in the IgG mouse or IgG rabbit samples was used as a baseline to compare to
their respective 5-methylcytosine or 5-hydroxymethylcytosine antibodies. This experiment was
presented as a measure of the fold change difference between the IgG controls and their
respective 5mC and 5hmC counterparts using the following equation:
Fold Change = 2-ΔΔC(t)
where ΔΔC(t) is the value obtained by subtracting the IgG cycle threshold values from the
experimental (5mC or 5hmC) cycle threshold value after normalization to the H2O blank cycle
threshold values. For experiments involving HEK293 cells, supernatants from
immunoprecipitated IgG controls were collected and used to quantify amount of input DNA
using qPCR.
Assessment of DNA-IPs
Endpoint PCR was performed to determine a visual difference between both 5mC and
5OH and their IgG controls. Primers used were for both the 12S and 16S regions of the
mitochondrial genome:
12S-Forward: 5′-AGTTCACCCTCTAAATCACCACG-3′
12S-Reverse: 5′-TGACTTGGGTTAATCGTGTGACC-3′
16S-Forward: 5′-ACCTTACTACCAGACAACCTTAGCC-3′
16S-Reverse: 5′-TAGCTGTTCTTAGGTAGCTCGTCTGG-3′
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12S and 16S master mixes were produced using 12.5µL of HotStart Taq DNA polymerase, 1µL
of 10µM forward and reverse primers and 8.5µL H2O per tube. 24µL of Master Mix, along with
1µL of sample DNA was placed into clear microfuge tubes while PCR was run at 35 cycles
under the following cycling conditions:
1. 950C for 15 minutes
2. 940C for 30 seconds
3. 550C for 30 seconds
4. 720C for 30 seconds
5. Go to Step 2 35 times
6. 720C for 5 minutes
7. 40C forever
H2O blank as well as input DNA from the supernatant collected during the MeDIP protocol was
used as both a negative and positive control respectively. PCR amplified products were then
resolved on a 1% agarose gel for 70 minutes at 100 volts.
Quantitative PCR measurement of mtDNA in DNA-IP samples
Quantitative PCR was carried out using the same primers and cycling conditions used for
Endpoint PCR. Samples were amplified over 35 cycles using Quantitect Sybr Green Dye
HotStart Taq mastermix from Qiagen. The following cycling conditions were used: A no
template control was run to detect any background amplification, while a standard curve was
produced using 10-fold serial dilutions to 1:1000 of the wild-type IDH1 IgG mouse control
sample following IP. Both IgGM and IgGR inputs were diluted 1:100 while samples treated with
the 5OH antibody were diluted 1:5. Dilution factors for each treatment of each sample were
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measured using the Opticon software and this data was expressed as a percentage of the input.
Furthermore, data was normalized to IDH 1 or IDH2 wild-type to determine the difference in
abundance of each epigenetic modification.
Treatment with Octyl-(D)-2-hydroxyglutarate
HEK293 cells were plated in 100mm dishes at 30-40% confluency and fed using 10%
FBS DMEM. Cells were left to incubate overnight in 10% CO2 incubator at 37⁰C. The following
day, cells were treated with either 1µL or 10µL of 10mM stock solution of octyl-(D)-2hydroxyglutarate (Toronto Research Chemicals Inc.) in DMSO to bring concentrations to 1µM
or 10µM respectively. A no-drug control was used in this experiment as well as a DMSO vector
control. Drug was left on plates for 48 hours and media was not removed. Cells were scraped
from dish after 48 hours and pelleted for DNA isolation. The DNeasy Blood and Tissue Kit from
Qiagen was used as previously described and samples were sonicated twice at high power for 15
minutes using intervals of 30 seconds on, 30 seconds off to obtain fragments of DNA between
200 and 500 base pairs. Sonicated samples were resolved on a 1% agarose gel for 70 minutes at
100 volts. MeDIP technique was followed as described above to isolate 5-methyl and 5hydroxymethyl residues found in cells. 12S and 16S rRNA regions of the mitochondrial genome
were amplified using both Endpoint and qPCR as described to determine the effect of this cell
permeable analog of 2-hydroxyglutarate on the mitochondrial epigenome. Conditions for PCR
were followed as described above.
Treatment with an IDH1 R132H Mutation Inhibitor, AGI5198
HEK293 cells that stably express the IDH1 R132H mutation were plated in 100mm
dishes at 30-40% confluency and fed using 10% FBS DMEM. Cells were left to incubate
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overnight in 10% CO2 incubator at 37⁰C. The following day, cells were treated with 5µL of
10mM stock solution of AGI-5198 drug, a known IDH1 R132H mutation inhibitor, bringing the
concentration of drug to 5µM. This stock solution was initially resuspended in DMSO. Both a
no-drug treated and DMSO control was used for this experiment. After drug treatment, cells
were harvested 48 and 144 hours later. Media was replaced 72 hours after initial treatment for
144 hours treated cell. Cells were scraped and pelleted for DNA isolation using the Qiagen
Tissue and Blood kit as previously described. Samples were sonicated and subjected to MeDIP
protocol as detailed above. To determine if this inhibitor drug had any effect on the
mitochondrial epigenome, the 12S and 16S primer pairs (listed above) were amplified using both
Endpoint and qPCR for a visual as well as quantitative determination.
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Chapter 3: Results
The effect of IDH mutations on mitochondrial epigenetics using the HCT-116 cell line
Preliminary studies were performed using HCT116 cells to determine if the IDH1 R132H
or IDH2 R172K mutations affect the levels of 5-methylcytosine and 5-hydroxymethylcytosine
found within the mitochondrial genome of this cell line. These studies were originally begun in
the summer of 2012 by Hannah Gardner. HCT-116 cells were used in these studies because they
have an abundance of mitochondria within each cell. Cells were transfected with the plasmids
shown in Table 1 to determine how either the cytoplasmic (IDH1) or mitochondrial (IDH2)
isoforms of IDH would affect the epigenome of the mitochondria. Co-transfection of IDH mutant
samples with the (D)-isoform of 2-HGDH was also carried out to determine whether changes in
the level of 5-hydroxymethylcytosine resulting from effects of mutant IDH could be rescued,
since this enzyme, under normal conditions, converts 2-hydroxyglutarate to α-ketoglutarate to
keep the levels of 2-HGlow within the cell. The 2-HGDH enzyme should therefore relieve the
competitive inhibition of the TET enzymes by 2-HG. A GFP control was used to visualize the
efficiency of transfection in this cell line.
Cells transfected with GFP were viewed under a fluorescence microscope 24 and 48
hours post transfection as a measure of transfection efficiency (Figure 3-1). After 24 post
transfection, 30-40% of cells glowed green under the microscope. 48 hours post-transfection,
approximately 75% of cells glowed green under the fluorescent microscope indicating the level
of transfection efficiency. After 48 hours, transfected cells were harvested for protein expression
analysis from the transfected plasmids. Once the protein concentration of each sample was
determined, immunoblotting was performed to determine protein expression level of each
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A

B

Figure 3-1: Determining transfection efficiency in HCT-116 cell line. Microscopy images of
GFP transfected HCT-116 cells 24 hours (A) and 48 hours (B) after initial transfection to
determine efficacy of transient transfection

35

FLAG

VDAC

Myc

VDAC

Figure 3-2: Analysis of protein expression levels of transiently transfected HCT-116 cells
using immunoblotting. IDH proteins were analyzed using a FLAG-specific antibody while
2HGDH proteins were analyzed using a Myc antibody. VDAC was used as a loading control.
These immunoblots were performed by Hannah Gardner.
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sample. FLAG-tagged IDH samples were examined using an antibody specific to the FLAG tag
located at the C-terminus of each IDH protein. A MYC antibody was used to visualize the
MYC-tagged 2-hydroxyglutarate dehydrogenase plasmids that were co-transfected into the
appropriate samples. A VDAC antibody was used to ensure equivalent loading of each sample
onto the gel as it is a common ion channel found on the surface of the outer mitochondrial
membrane. As can be seen in Figure 3-2, each sample expressed the appropriate IDH plasmid
while co-transfected samples expressed both FLAG-tagged IDH as well as the MYC-tagged (D)2HGDH plasmid. Samples transfected with the L-isoform of 2HGDH did not appear to express
the epitope tag encoded on its plasmid, although DNA sequence analysis verified the correct inframe cloning of this cDNA.
After expression levels were confirmed, the cells pelleted for DNA extraction were
thawed and total cellular DNA, which includes mitochondrial DNA, was isolated from each
sample. These samples were sonicated, to shear the DNA to a length of 200-500 base pairs to
avoid amplifying modified DNA outside the regions of interest. The appropriate sonication of
each sample was confirmed using a 1% agarose gel stained with Ethidium Bromide. Once the
proper length of DNA was obtained for each sample, MeDIP was performed as detailed in the
methods section. After MeDIP, endpoint PCR was utilized at 35 cycles to obtain a visual
representation of how much modified DNA was present in each sample compared to its specific
IgG control (Figure 3-3). The signal for the 5-hydroxymethylcytosine residues found in the 12S
and 16S regions of the mitochondrial genome is very robust and well above its respective IgG
Rabbit control antibody which is interpreted as a measure of assay background. In contrast, the
5-methylcytosine signal is low and frequently cannot be distinguished from its IgG Mouse
control using endpoint PCR.
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To obtain a quantitative difference between IDH wild-type and IDH mutant samples,
qPCR was performed. Amplification of the 12S rRNA region of the mitochondrial genome
(Figure 3-4), indicates that the introduction of the IDH1 R132H mutation results in a dramatic
decrease in the level of 5hmC residues, about 4.5 fold relative to the levels of 5hmC in the IDH1
wild-type transfected sample. A slight increase in the abundance of 5mC residues relative to that
found in the IDH1 wild-type sample is found in the mitochondrial genome when the IDH1
R132H mutation is expressed in this HCT116 cell line. However, the signal obtained from the 5methylcytosine specific antibody is low, suggesting a low level of 5-methylcytosine residues in
the mitochondrial genome. Background signal obtained with the mouse IgG control antibody is
often as high as the 5mC antibody signal. Previous studies in the lab have shown substantial lotto-lot variation in the background signal with mouse IgG. Multiple IgG mouse control antibodies
will be tested in future experiments to more accurately determine the level of 5-methylcytosine
modification found in the mitochondrial genome. However, since the level of 5hydroxymethylcytosine found in these samples is well above baseline IgG control levels, it is
reasonable to conclude that there is a preponderance of 5hmC modified DNA in the
mitochondrial genome although the function of this modification in the mitochondria remains to
be determined. When analyzing the level of 5hmC modified DNA in the 16S rRNA region after
the incorporation of the IDH1 mutation, a similar trend is found as that seen in the 12S rRNA
region (Figure 3-5). Once again, a 4.5 fold decrease in 5hmC signal is observed when mutant
IDH1 is expressed compared to the IDH1 wild-type sample, indicating a substantial reduction in
the amount of 5hmC in the 16S rRNA region of the mitochondrial genome. When analyzing the
5mC content present in the 16S rRNA region, we observed that the levels of 5mC increase in
IDH1 mutated HCT-116 cells compared to the wild-type sample. However, once again, the
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abundance of 5mC residues found in the 16S rRNA region of the mitochondrial DNA does not
rise above the baseline IgG mouse control levels indicating a problem with this lot of IgG control
antibody as previously mentioned.
Results obtained with transfection of the IDH2 R172K mutation, were somewhat
different to those seen with the IDH1 R132H mutation. In IDH2 mutant transfected HCT116
cells, the levels of both 5mC and 5hmC are reduced when compared to their IDH2 wild-type
counterparts. These results were similar in both the 12S (Figure 3-4) and 16S (Figure 3-5)
regions of the mitochondrial genome. In the 12S rRNA region, there is a clear 4-fold drop in the
levels of both 5hmC and 5mC. Examination of the 16S rRNA region indicates a more modest 2fold decrease in 5hmC level when comparing IDH2 wild-type to IDH2 mutant while the amount
of 5mC modified DNA present in this region is nearly 90% less in the IDH2 mutant sample
compared to wild-type. Fortunately, the level of 5mC in both the ribosomal genes is above
baseline (IgG control) in the IDH2 wild-type transfected cells however, the level falls below
baseline with the introduction of the IDH2 mutation. The levels of 5mC and 5hmC were
measured in the samples that were co-transfected with the D2 isoform of 2-HGDH as well since
the (D)-isoform of 2-hydroxyglutarate is solely produced by these IDH mutations. With the
introduction of this enzyme, the levels of 5hmC and 5mC begin to rise towards levels similar to
those found in the IDH2 wild-type sample. In the 12S rRNA gene region, 5hmC and 5mC levels
rise by 50% and 150% respectively compared to the IDH2 mutated samples. Since 2-HGDH
functions to convert 2-HG to α-ketoglutarate, the effect of this enzyme was expected to reverse
the decrease in 5hmC levels caused by mutant IDH through relief of competitive inhibition of
the TET enzymes by 2-HG. The increase in 5mC levels in this co-transfected sample was
opposite to that expected and likely reflects the very high IgG control in the mutant IDH samples
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12S

16S

Figure 3-3: Example of endpoint PCR of HCT116 cells after transient transfection of IDH1
wild-type plasmid. DNA that was not used for MeDIP protocol was used for Input control. Both
the 12S and 16S regions of the mitochondrial genome were analyzed using specific primers.
PCR produce (200bp) was resolved on a 1% agarose gel. IgG Mouse compares to 5methylcytosine while IgG Rabbit is compared to the signal produced by the 5hydroxymethylcytosine antibody.
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Figure 3-4: Expression of mutant IDH causes a reduction in the level of 5hmC in the 12S
gene of the mitochondrial genome. Shown is a graphical representation of the effects of IDH
enzymes on the abundance of 5-methylcytosine and 5-hydroxymethylcytosine in the 12S rRNA
region of the mitochondrial genome. Samples were normalized to their respective IgG controls.
Both IDH1 (A) and IDH2 (B) are displayed.
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Figure 3-5: Expression of mutant IDH causes a reduction in the level of 5hmC in the 16S
gene of the mitochondrial genome. Shown is a graphical representation of the effects of IDH
enzymes on the abundance of 5-methylcytosine and 5-hydroxymethylcytosine in the 16S
ribosomal RNA region of the mitochondrial genome. Samples were normalized to their
respective IgG controls. Both IDH1 (A) and IDH2 (B) are displayed.
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(Figures 3-4 and 3-5). However, a possible novel interaction between 2-HGDH and the
methylation machinery of the mitochondria cannot be ruled out at this time. Further experiments
will need to be performed to understand which of these two possibilities is at play. Interestingly,
when analyzing the 16S rRNA gene cotransfection with IDH mutant and (D)-2HGDH, the level
of 5mC increases by nearly 2-fold when compared to the level of 5mC found in the IDH2
mutated sample while the 5hmC level decreases by about 0.5 fold compared to IDH2 mutant
levels. This result is different from thatfound in the nuclear genome and the 12S rRNA region,
pointing to a possibly different mechanism of action for cytosine modification between these two
ribosomal RNA regions of the mitochondrial genome.
The effect of IDH mutations on mitochondrial epigenetics using the HEK293 cell line
HEK293 cells were used to validate whether the effects of IDH mutations on
mitochondrial epigenetics, observed using the HCT116 human cancer cell line, could be
replicated in another cell line. The embryonic kidney cell line has been used by several other labs
to uncover the role of IDH mutation on nuclear epigenetics and is much less mutated than the
HCT-116 cell line. Using either wild-type or mutant IDH containing plasmids as well as cotransfections using the different 2HGDH isoforms (Table 1), transient transfection was
performed once cells reached 70-80% confluency on their respective plates as previously
described. Photomicrographs of the GFP plate were taken 24 hours and 48 hours after
transfection to determine the efficiency of the transfection. As shown in Figure 3-6, about 50%
of the cells fluoresce under the microscope after 24 hours post-transfection and about 90% of the
cells fluoresce 48 hours after transfection. After protein concentrations were determined,
immunoblotting was carried out as described using a VDAC loading control to assess equivalent
loading of each of the samples onto the blot. Each of the IDH samples (samples 1-12)
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A

B

Figure 3-6: Determination of Transfection Efficiency of HEK293 cells. Microscopy image of
GFP-expressing HEK293 cells 24 hours (A) and 48 hours (B) after initial transient transfection.
These images were used as rough estimates of transfection efficiency.

44

FLAG

Myc

VDAC

Figure 3-7: Immunoblots of transient transfection using HEK293 cell line. IDH proteins
were analyzed using a FLAG-specific antibody while 2HGDH proteins were analyzed using a
Myc antibody. VDAC was used as a loading control.
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appropriately express the epitope-tagged protein on the plasmid that was transfected into the
cells whether they were IDH1 wild-type or mutant or IDH2 wild-type or mutant (Figure 3-7).
Interestingly, all IDH2 expressing plasmids displayed two bands at 46 and 50 kD. These bands
represent the different subcellular locations of the protein as 39 amino acids are cleaved from the
N-terminus upon entry into the mitochondria. The upper band represents the protein before
mitochondrial localization as not all of the protein had entered this organelle before harvesting of
the cells for protein extract while the lower band represents IDH2 protein that had entered the
mitochondria. As before, the epitope tag encoded on the L2HGDH plasmid was not detectable.
To detect this protein, an antibody directed against the protein itself may be necessary if
available and alternative or N-terminal tags will be tested. The D2HGDH protein was expressed
very well. No protein tagged with either FLAG or Myc was expressed in the blots of either the
vector control or the GFP control used in this experiment indicating proper transfection of all
samples. After determining that each sample expressed the appropriate proteins, the total cellular
DNA was isolated. Pure DNA was sonicated to lengths between 200 to 500 base pairs and
resolved on a 1% agarose gel to ensure that qPCR would detect modified residues only in the
vicinity of the amplified fragment (Figure 3-8). For these experiments, the supernatant of both
the IgG Mouse and IgG Rabbit samples were collected and used to determine input in order to
control for variability in the amount of DNA used in each assay. The 5mC and 5hmC values
would be measured as a percentage of input when compared to their IgG mouse and IgG rabbit
controls respectively. Once the MeDIP was performed, endpoint PCR was used to validate the
success of the IP (Figure 3-9). As can be seen, when amplifying the 12S and 16S rRNA regions
of the mitochondrial genome, the IgG rabbit control gives a much fainter signal than its 5hydroxymethylcytosine counterpart indicating an abundance of 5hmC in this sample.
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500 bp
200 bp

Figure 3-8: Sonication of purified DNA using HEK293 cells. Samples were sonicated between
200 to 500 bp to produce small enough DNA fragments useful for MeDIP protocol. Sonicated
samples were resolved on a 1% agarose gel run for 70 minutes at 100 volts.
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Figure 3-9: Endpoint PCR of HEK293 cells. Samples shown were transiently transfected with
IDH1 mutant plasmid. DNA that was not used for MeDIP protocol was used for Input control.
Both the 12S and 16S regions of the mitochondrial genome were analyzed using specific
primers. The 200 bp amplicon was resolved on a 1% agarose gel.
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Unfortunately, the 5mC signal cannot be distinguished from its IgG mouse signal leading one to
conclude that a difference in abundance of 5mC compared to background cannot be determined
using the endpoint PCR method. It is possible that there is a much smaller amount of methylated
cytosine residues in the mitochondrial genome. To better understand how IDH mutation affects
the abundance of DNA modifications in the mitochondrial, qPCR was performed to obtain a
quantitative measurement of whether and how the levels of 5hmC and 5mC areaffected
following expression of IDH mutations.
As shown in Figure 3-10, in the 12S rRNA region of the mitochondrial genome,
enrichment for 5hmC is substantially greater than the IgG rabbit control for each sample with the
introduction of either IDH1 or IDH2 wild-type plasmids. This 5hmC signal is reduced by 50% or
greater when IDH is mutated, most likely due to competitive inhibition of the TET enzymes by
the 2-hydroxyglutarate produced by this enzyme. This effect is similar to that observed in HCT116 experiments. The decrease in 5hmC content in HEK293 cells was partially rescued by cotransfection with the (D)-2-HGDH enzyme, which is expected to convert excess 2-HG to αketoglutarate, thereby partially relieving the inhibition placed on the TET enzymes by 2-HG.
While restoration of 5hmC levels was observed by expression of the 2-HGDH enzyme, the levels
did not reach those of the IDH wild-type samples. The amount of 2-HG produced by these
mutant enzymes is substantial and may be too large for the 2-HGDH enzyme to convert back to
α-ketoglutarate during the 48 hour time course of this experiment. Since the physiological
concentration of the 2-HG oncometabolite is very low in cells (0.1nM), the kinetic parameters of
this enzyme in the face of millimolar concentrations are not yet characterized. It is also important
to keep in mind that the data presented here represent one of three biological replicates and the
data for the other replicates are still being analyzed.
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The 16S rRNA region, showed similar results to those shown in the 12S rRNA region.
The wild-type IDH1 5hmC level is high compared to its IgG rabbit control (Figure 3-11), while
transfection with plasmid expressing mutant IDH1 results in a 50% reduction in the level of
5hmC in comparison to the IDH wild-type level, indicating loss of 5hmC at the 16S rRNA
region of the mitochondrial genome. Co-transfection with (D)-2-HGDH partially restores the
level of 5hmC, likely due to the relief of the inhibition placed on the TET enzymes by 2-HG.
Surprisingly, for IDH2, the mitochondrial isoform of this enzyme, the levels of 5hmC in the 16S
region, are very similar between IDH2 mutant and wild-type IDH2-transfection. This trend is
somewhat different from that observed in the HCT-116 cell line and in nuclear genomic DNA
once again demonstrating the possibility that these different mitochondrial genes react
independently of each other to stimuli. Again, it is also important to realize that this is one single
biological repeat of three so the trend may be specific to this repeat and will need to be analyzed
along with the other repeats to determine the biological effect of this mutated enzyme. Since the
concentration of α-ketoglutarate in the mitochondria is much greater than in the cytoplasm, the
conversion of this metabolite to 2-HG may not be as pronounced when IDH2 is mutated as
compared to IDH1. Mass spectrometry will be used in future experiments to determine the level
of 2-HG produced by each mutation.
The changes in levels of 5-methylcytosine in DNA samples from these transfected HEK
cells were inverse to those seen in the levels of 5-hydroxymethylcytosine for IDH1 transfections.
When the IDH1 wild-type plasmid was introduced into HEK293 cells the levels of 5mC were
below the baseline levels determined by the IgG controls in both the 12s and 16s regions of
mitochondrial DNA but the introduction of a IDH1 R132H mutation brought about a rise, above
baseline, in the levels of methylation found in these ribosomal gene regions. This low signal
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Figure 3-10: Analysis of epigenetic modification of the 12S rRNA gene after transfection of
HEK293 cells with wt and mutant IDH. The abundance of 5-hydroxymethylcytosine (A) and
5-methylcytosine (B) residues found in the 12S ribosomal RNA region of human mitochondrial
DNA after transfection of HEK293 cells expressed as % of input DNA.

51

A. 5hmC

7
5hmC (% of Input)

6
5
4
3
2

IgGR

1

5hmC

0

5mC (% of Input)

B. 5mC

9
8
7
6
5
4
3
2
1
0

IgGM
5mC

Figure 3-11: Analysis of epigenetic modification of the 16S rRNA gene after transfection of
HEK293 cells with wt and mutant IDH. The abundance of 5-hydroxymethylcytosine (A) and
5-methylcytosine (B) residues found in the 16S ribosomal RNA region of human mitochondrial
DNA after transfection of HEK293 cells, expressed as % of input DNA.
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makes it difficult to determine the levels of 5mC in the mitochondrial genome when IDH is not
mutated and thus these samples cannot be adequately compared to each other. It is also difficult
to establish a trend since the levels of the IgG mouse control antibody differ drastically between
each sample. This technical issue is currently being resolved in the lab.
A similar trend exists when IDH2 is mutated in that the percentage of methylated
cytosine residues rises compared to the levels found in IDH2 wild-type samples. Also of interest
is that when IDH2 mutant samples were co-transfected with (D)-2-HGDH, the level of 5mC
decreased which may mean that this enzyme is working to convert excess 2-HG back to αketoglutarate thereby relieving the inhibition placed on the TET enzymes and allowing for more
hydroxylation of 5-methylcytosine residues. This trend is similar in both the 12S and 16S rRNA
gene regions. This experiment was repeated in three separate biological repeats using HEK293
cells however, as previously mentioned, only one repeat is shown in the figures above. This data
is currently being analyzed further to determine if the trends above are consistent between each
biological repeat. Also, since the IgG mouse control antibody provides different levels of
enrichment between samples, it is not possible to accurately determine how IDH mutations affect
the methylation of cytosine residues in the mitochondria, and we will test different mouse IgG
samples to obtain material that consistently yields low background values..
The effect of Long-Term Expression of IDH mutants
To determine how IDH mutations affect the mitochondrial epigenome over time, cell
lines stably expressing the IDH1 wild-type and mutant cDNAs, as well as those expressing IDH2
wild-type and mutant cDNAs, were created. This experiment was performed to determine if a
similar hypermethylator phenotype as that produced in the nuclear genome develops in the
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mitochondria and determine whether these mutant enzymes cause a change in mitochondrial
gene expression or metabolic function of the mitochondria. This experiment was performed
using HEK293 cells and cells were transfected and subjected to neomycin selection (1mg/mL) to
eliminate cells that did not integrate the IDH plasmids into their genomes. As this DNA is
integrated randomly into the genome and might be present in multiple copies, immunoblotting
was performed to determine the level of expression of the transgene in each clone. Since these
integration events are random and can occur multiple times in the genome, many clones were
isolated for each plasmid and analyzed for protein expression using the FLAG antibody. To
control for these multiple integration events, master cultures were also created, analyzed for
protein expression and frozen for later use to determine the overall average effect of these mutant
IDH proteins. Once confirmed, three clones of each IDH-expressing sample were analyzed to
determine if the level of this enzyme being expressed was physiologically relevant to the levels
found in normally untransfected cells. This was done to ensure that changes in the levels of
5hmC and 5mC were relevant to those found in human tumor samples. The endogenous levels of
IDH were determined using an antibody specific for IDH2 that was able to recognize both the
IDH1 and IDH2 isoforms present in the cell. These stable clones were compared to untransfected
control HEK293 cells to determine the degree of overexpression of each in the stable cell culture.
VDAC was used as a loading control (Figure 3-12) as well as a Cyclophilin A antibody which
recognizes a ubiquitously expressed nuclear receptor protein. The Cyclophilin A antibody was
used for the IDH2 expressing clones (Figure 3-13) since we observed fluctuating levels of
VDAC signal in these experiments, possibly related to effects on mitochondrial integrity. The
clones that were chosen (Figure 3-12 & Figure 3-13) expressed their FLAG-tagged IDH
plasmids. All clones expressed either equivalent or greater amounts of the IDH protein,
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Figure 3-12: IDH expression levels in IDH1 mutant and wild-type stable clones. Three
separate wild-type clones as well as three separate IDH1 mutant expressing clones were analyzed
to determine level of transgene expression. An untransfected control was used to determine
levels of endogenous IDH expressed in HEK293 cells. VDAC was used as a loading control to
assess equal loading of each sample.

55

IDH2 wt

IDH2 mut

FLAG
(Transgene)
IDH
(Endogenous
+ Transgene)
Cyclophilin A
(Loading Ctrl)

Figure 3-13: IDH expression levels in IDH2 mutant and wild-type stable clones. Three
separate wild-type and mutant expressing clones were analyzed to determine level of transgene
expression. An untransfected control was used to determine levels of endogenous IDH expressed
in HEK293 cells. Cyclophilin A was used as a loading control to assess equal loading of each
sample.
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indicating a level of expression equivalent or greater to the endogenous levels of the IDH protein
in HEK293 cells. In regards to the IDH2 samples, different band sizes were observed indicating
the degree of transport into the mitochondria since the mitochondrial leader peptide is cleaved
after the protein enters the mitochondria. As the protein is being adequately expressed in these
clones, two clones (the second and third clone also) were kept. The second and third clones of
each sample were kept and cells will be grown over time to determine how the levels of 5methylcytosine and 5-hydroxymethylcytosine change over multiple passages in the
mitochondrial genome by utilizing the MeDIP technique.
Effect of Octyl-2-hydroxyglutarate on the 5-hydroxymethylcytosine content of the
mitochondrial genome
As it is known that the production of 2-HG has a pronounced inhibitory effect on the TET
dioxygenase family and causes a change in the epigenome of mammalian DNA, cells were
treated with a cell-permeable analog of this oncometabolite, octyl-(D)-2-hydroxyglutarate, to
determine how it affects the 5-methylcytosine content of the mitochondrial genome, specifically
the 12S and 16S ribosomal regions. Mutant IDH also oxidizes NADPH to NADP+ thereby
decreasing the stores of NADPH available in the cell. This may be detrimental to the cell as
NADPH is necessary for many cellular processes such as macromolecular biosynthesis and
antioxidant properties. In all tumor samples analyzed to date, the IDH mutations solely produce
the D-isoform of 2-HG so this experiment should replicate what is found in vivo. This analog is
able to penetrate both the cell and mitochondrial membranes and would be expected to affect
processes in all compartments. Also, using this molecule, we bypass any adverse effects of an
imbalanced NADPH/NADP+ ratio on the mitochondria with respect to oxidative
phosphorylation and energy production. HEK293 cells were treated with either 1µM or 10µM
57

octyl-(D)-2-HG and DNA was harvested for MeDIP analysis. We included a no drug and DMSO
control, since the octyl-2-HG is dissolved in DMSO. After MeDIP, endpoint PCR was performed
to obtain a visual representation of how the different levels of 5mC and 5hmC appear in the
mitochondria using primer sets for the 12S and 16S rRNA regions of the genome (Figure 3-14).
Results of endpoint PCR were similar to past examples in that the 5hmC signal was much greater
compared to its IgG rabbit control while the 5mC signal remained difficult to distinguish from
the signal generated by the IgG mouse control.
When analyzed using qPCR, the level of 5-hydroxymethylcytosine decreased by about
50% in the 12S rRNA region and almost 90% in the 16S rRNA region (Figure 3-15) in samples
treated with octyl-2-HG as compared to the untreated controls. The DMSO control also had
reduced 5hmC content in the mitochondrial genome indicating an effect of this molecule on
mitochondrial epigenetics. Interestingly, the level of 5hmC remained constant even after a tenfold increase in octyl-(D)-2-HG concentration suggesting that TET enzymes can be inhibited
fairly easily by this metabolite at low concentrations and that the concentration of this molecule
is tightly regulated in cells. The decrease in 5hmC produced by this drug is similar to that
produced by the mutant IDH proteins implying that the amount of 2-hydroxyglutarate necessary
for inhibition of TET enzymes that locate to the mitochondria is between 1-10µM and can
produce an effect on mitochondrial epigenetics fairly quickly.
The effect of the cell permeable analog of 2-hydroxyglutarate on 5mC levels in HEK
293 cells was again difficult to assess, due to the high and very variable background signal seen
with the mouse IgC antibody control, (Figure 3-16) in both the 12S and 16S regions of this
genome. Also of note, is that the DMSO vector control, which has a negative effect on 5hmC
content in the mitochondria, may also have an effect on 5mC levels in the organelle although the
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Figure 3-14: Visual representation of 12S and 16S rRNA regions after treatment with cell
permeable 2-hydroxyglutarate. Example of endpoint PCR of immunoprecipitated DNA from
HEK293 cells after treatment with 1µM octyl-(D)-2-hydroxyglutarate. Both the 12S and 16S
rRNA regions of the mitochondrial genome were analyzed using specific primers. The 200bp
amplicon was resolved on a 1% agarose gel.
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Figure 3-15: Treatment of HEK293 cells with cell permeable 2-hydroxyglutarate results in
reduced 5hmC content in the mitochondrial genome. 12S (A) and 16S (B) rRNA gene
regions were analyzed after treatment with 1µM and 10µM concentrations of octyl-(D)-2-HG.
60

A
5
4.5
4

% of Input

3.5
3
IgGM

2.5

5mC

2
1.5
1
0.5
0
No Drug

Vehicle

1uM 2-HG

10uM 2-HG

B
12
10

% of Input

8
IgGM

6

5mC
4
2
0
No Drug

Vehicle

1uM 2-HG

10uM 2-HG

Figure 3-16: Treatment of HEK293 cells with cell permeable 2-hydroxyglutarate results in
indeterminate changes in 5mC content in the mitochondrial genome. 12S (A) and 16S (B)
rRNA gene regions were analyzedafter treatment with 1µM and 10µM concentrations of octyl(D)-2-HG.
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signal produced is below the IgG baseline value making any comparison impossible. This
experiment provides clear evidence that 2-HG causes a competitive inhibition of the enzymes
necessary for hydroxymethylation of the mitochondrial genome. However, an effect of the
oncometabolite on cytosine methylation of the mitochondrial genome is still an open question.
Use of an IDH1 Mutation Inhibitor to Rescue 5-hydroxymethylcytosine levels
To more fully understand the effect of IDH mutations in tumorigenesis and to determine
if the effects can be reversed and used as a clinical therapeutic, a company headquartered in
Cambridge, Massachusetts (Agios) developed a molecule that can specifically inhibit the IDH1
R132H mutation and restore cellular differentiation potential and nuclear epigenetic marks while
not affecting IDH1 wild-type tumors (62). As the molecule developed by Agios to inhibit IDH2
was created against the IDH2 R140Q mutation, our studies focused on the IDH1 mutant inhibitor
which is specific for the R132H mutation (80). If the new activity of mutant IDH, which
produces 2-HG, is responsible for a reduction in 5hmC in the mtDNA, we would expect that
specific inhibition of this activity would restore levels of 5hmC in the mitochondrial DNA.
Accordingly, we tested whether a similar result could be achieved in mitochondrial DNA and
restore the level of 5hmC in this genome thereby relieving inhibition of the TET enzymes by 2HG. AGI-5198 (5µM) was incubated with HEK293 cells that stably express the IDH1 R132H
mutation. Drug treated cells were harvested at different time points and pelleted for DNA
purification to determine the effects of this drug on the mitochondrial epigenetics of the cell. An
untreated and DMSO treated sample were used as controls for this experiment. Afterwards,
MeDIP was performed to harvest all of the DNA molecules that contain either 5-methylcytosine
or 5-hydroxymethylcytosine residues. After MeDIP, endpoint PCR using primer sets for the 12S
and 16S rRNA regions of the mitochondrial genome was performed to determine the success rate
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of the IP prior to proceeding to qPCR. An example of the end-point PCR is shown in Figure 317. Once again, the signal produced by the 5hmC sample was much more apparent than its IgG
rabbit control while the level of 5mC in the mitochondrial ribosome genes remained diminished
and close to the level of the IgG mouse control. It is apparent that levels of methylation in the
two ribosomal regions of the DNA are kept at a minimal level while hydroxymethylation
remains high in these areas.
qPCR was employed as before to determine if the quantity of 5hmC residues in the
mitochondrial genome increases after treating cells with AGI-5198. Treatment with this drug
does in fact result in an increase in 5hmC content in the 12S and 16S region of mtDNA (Figure
3-18). In the 16S rRNA region, there is a time-dependent response to the IDH1 mutant inhibitor
as the level of 5hmC rises above the level of the no-drug control when exposed to this drug for
short (48 hours) and long (144 hours) periods of time. In the 12S rRNA region, a positive trend
exists between 5hmC levels and time exposed to AGI-5198. However, it is interesting to note
that when evaluating the 12S region, the percentage of the 5hmC modification is greater than
either of the treated samples indicating a possible technical problem with this assay. Cells used
for the no-drug control will need to be analyzed to determine if the IDH1 mutation is expressed
appropriately.
The level of 5-methylcytosine content was also measured in these AGI-5198 treated cells.
As seen in Figure 3-19, this drug has an inverse effect on the level of 5mC in the mitochondrial
genome. When treated with AGI-5198 over time, the level of 5mC in the 12S rRNA region
decreases to that of the IgG control. This pattern is similar to that seen in the IDH1 wild-type
transfected cell samples, indicating that the levels of 5-methylcytosine in the 12S region are kept
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Figure 3-17: Visual representation of 12S and 16S rRNA regions after treatment with
IDH1 mutant inhibitor. Example of endpoint PCR of HEK293 cells used in experiment to
determine how AGI-5198 affects mitochondrial epigenetics. Both the 12S and 16S rRNA regions
of the mitochondrial genome were analyzed using specific primers. The 200bp amplicon was
resolved on a 1% agarose gel.
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Figure 3-18: Evaluation of levels of 5hmC after exposure to a specific inhibitor of mutant
IDH1. IDH1 mutant expressing cells were treated with AGI-5198 for 48 or 144 hours to
determine if levels of 5hmC could be restored in the mitochondrial 12S (A) and 16S (B) rRNA
regions.
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Figure 3-19: Evaluation of levels of 5mC after exposure to a specific inhibitor of mutant
IDH1. IDH1 mutant expressing cells were treated with AGI-5198 for 48 or 144 hours to
determine if levels of 5mC could be reduced in the mitochondrial rRNA regions. Both the 12S
(A) and 16S (B) regions were analyzed.
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at a minimal level. In the 16S rRNA region, all the treated samples are below their respective
IgG controls making it difficult to determine if a correlation exists between IDH1 mutant
inhibition and the level of 5mC in the mitochondria. As the level of 5mC is so low in the no-drug
treated controls, it is possible that the cells used did not accurately express the IDH1 R132H
mutation and will need to be analyzed to determine expression of this enzyme in this cell line.
These results indicate that with the addition of the IDH1 mutant inhibitor AGI-5198 to cells
expressing this aberrant enzyme, the level of 5hmC can begin to be restored to IDH1 wild-type
levels with a simultaneous decrease in the level of 5mC over time. This compound inhibits the
oncogenic function of mutant IDH1in producing 2-HG from α-ketoglutarate, thereby relieving
inhibition of TET enzymes and allowing for adequate hydroxylation of 5-methylcytosine
residues in the mitochondrial DNA.
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Chapter 4: Discussion
Aberrant Metabolism in Cancer: Understanding the Warburg Effect
In the 1950s Dr. Otto Warburg published his seminal paper on the theory of aerobic
glycolysis in cancer, which stated that cancer cells preferentially produce ATP via lactate
production in the glycolytic pathway instead of using the oxidative phosphorylation pathway
typically used by differentiated cells (81). Since then, much work has been done to try to
understand this hypothesis.
In normal cells, ATP is commonly produced via the electron transport chain (ETC) found
exclusively in the inner membrane of the mitochondria, the “powerhouse” of the cell (Figure 41). This process utilizes NADH, NADPH and FADH2, known electron acceptors produced via
the tricarboxylic acid cycle, to carry electrons to the different complexes of the ETC. These
electrons are produced via dehydrogenase reactions in the mitochondria in the form of a hydride
ion (H-). The dehydrogenase reaction receives two hydrogen atoms from its substrate, the
hydride ion just mentioned and a hydrogen ion (H+) which is fluxed out of the mitochondrial
inner membrane. The electrons produced are carried between the electron acceptors of the five
complexes of the oxidative phosphorylation chain where they end up combining with O2 to
create a water molecule. Three of the five complexes (Complex I, III, and IV) subsequently
produce a hydrogen ion gradient as electrons are passed through the ETC. This proton gradient is
utilized by the fifth complex in the electron transport chain, ATP Synthase to produce ATP from
ADP and inorganic phosphate (Pi). This process is typically regulated by the ADP/ATP ratio
available as a measure of energy demands for the cell.
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Figure 4-1: Diagram of oxidative phosphorylation as it occurs in normally dividing cells
within the inner membrane of the mitochondria. NADH is produced via the TCA cycle and
shuttled to Complex I where electrons are moved to differing complexes to create a proton
gradient. Proton gradient is utilized in the generation of ATP by Complex V (ATP Synthase).
Figure adapted from Readnower, 2011.
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In cancer, cells use a different pathway to achieve rapid ATP production. This pathway,
termed aerobic glycolysis, utilizes the glycolytic pathway to convert glucose into lactate. In
normal cells, this pathway operates in a hypoxic environment when energy demands are high
such as in strenuous exercise. Although glycolysis is much faster at producing ATP, less ATP is
produced (36). Cancer cells typically utilize this pathway for faster energy production, even in
the presence of oxygen, to maximize tumor growth. While it is debated as to why this shift in
ATP production occurs, the rapid uptake of glucose by cancer cells has been employed as a
clinical tool in tumor screening and detection. [18F]fluorodeoxyglucose positron emission
tomography imaging, or FDG-PET, has been used to detect areas of high glucose uptake in the
body by using radioactively labeled glucose analogs and has proved highly effective in detecting
and monitoring tumors.
A shift to aerobic glycolysis in cancer cells is usually accompanied by a reduction in
OXPHOS, achieved through unknown mechanisms. Thus, identifying oncogenic processes that
directly affect mitochondrial function in general and oxidative phosphorylation in particular are
critical to our understanding of these complex metabolic reprogramming events. As described in
this thesis, we have begun a study aimed at understanding whether the production of the
oncometabolite, 2-hydroxyglutarate, as a result of a gain-of-function mutation commonly found
in different tumors, plays a role in reprogramming metabolism through modification of the
mitochondrial genome.
Role of Mitochondria in disease
Dr. Warburg also postulated that the mitochondria found in cancerous cells are abnormal
and become dysfunctional leading to alterations in the energy producing pathway of these cells.
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While much study has been put into understand the energy portion of the Warburg effect,
understanding of the mitochondrial aspect of his theory has remained somewhat lacking over the
past few decades and continues to be controversial as some reports claim that mitochondrial
function remains normal after tumorigenesis and OXPHOS is uninterrupted (Ward & Thompson,
2012).
The endosymbiotic theory states that the mitochondrial genome developed from a
bacterial species that was engulfed by a primitive eukaryotic cell and which has retained a key
role in ATP production in eukaryotes to this day. While most of the genetic material encoded by
this ancestral endosymbiont has been transferred to the eukaryotic nuclear genome, several key
enzymes remain encoded on the mitochondrial genome, along with rRNAs and tRNAs required
for mitochondrial transcription and translation, which more closely resembles that of
prokaryotes. The human mitochondrial genome, as mentioned earlier, is 16.6 kilobases in length
and encodes 13 proteins integral to the function of the electron transport chain and therefore
generation of ATP in the cell. Of these thirteen proteins, 7 are included in Complex I, 1 is
included in Complex III, 3 are part of Complex IV and 2 are found in Complex V. One reason
why these 13 proteins are retained on the mitochondrial genome is that they are highly
hydrophobic and are difficult to import into the mitochondria from the nucleus. Another proposal
of this theory is that these proteins are vital to the metabolic control of the cell and are thus
regulated by the redox status of the cell (3) which is further emphasized by the relationship that
exists between reactive oxygen species production and mitochondrial dysfunction.
The remaining proteins required for oxidative phosphorylation are encoded on the
nuclear genome, pointing to a need for coordinate control of gene expression between
mitochondria and nucleus. Epigenetic mechanisms are critical for regulation of gene expression
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in the nucleus. Mitochondrial epigenetic mechanisms, recently described by our laboratory (68)
have been implicated in altering mitochondrial gene transcription, and others have suggested a
role for epigenetics in a retrograde signaling capacity between mitochondria and nucleus (69).
These proposed interconnections led us to hypothesize that cancer related mutations in genes
involved in intermediary metabolism, might play a role in dysregulating the balance between
nuclear and mitochondrial gene expression (48).
During oxidative phosphorylation, electron carriers found in Complex I and Complex III
are able to pass an electron to an O2 molecule creating the superoxide free radical .O2-. This free
radical is highly reactive and can produce the hydroxyl free radical .OH as well which can
damage metabolic enzymes, membrane lipids and nucleic acids. To keep free radical
concentrations low, cells utilize the superoxide dismutase enzyme to convert these reactive
oxygen species to oxygen and hydrogen peroxide which is then converted to water and rendered
harmless by the glutathione peroxidase enzyme. Unfortunately, in some instances, ROS
production is elevated beyond the level that these enzymes can control and can have serious
pathologic effects on mitochondria function. Also of importance is that the mitochondrial DNA
polymerase (mtPOLG) lacks a superb proofreading ability so that mutations in the mitochondrial
genome arise over time (75). These two problems can lead to mitochondrial dysfunction, and can
cause muscle weakness, decreased psychomotor skills and decreased bone density, signs typical
of the ageing process. This buildup of ROS species and mitochondrial mutations has been
implicated in various neurodegenerative diseases as well in Alzheimer’s disease, Parkinson’s
disease, and Huntington’s disease.
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Transcription of the Mitochondrial Genome
While the 13 protein-coding genes are integral to the oxidative phosphorylation pathway,
the mitochondrial genome also encodes 2 ribosomal RNAs and 22 transfer RNAs. Early in vitro
studies performed in human cells using 5’ and 3’ end labeling of mitochondrial transcripts
showed that two separate polycistronic messages are encoded on the mitochondrial heavy strand
while one message is encoded on the light strand of the genome (53). One message encodes the
two ribosmomal RNA genes, 12S and 16S, from a promoter termed HSP1 (Heavy Strand
Promoter), located 16 base pairs upstream of the gene that encodes the phenylalanine-specific
tRNA. In fact, the rRNAs are transcribed 10 to 30 more often than the protein-coding genes in
the mitochondrial genome. These ribosomal components assist in the translation of the proteincoding genes which are transcribed from the second start site, HSP2. This promoter initiates
transcription near the 5’ end of the 12S rRNA gene and encodes essentially the entire heavy
strand. A third message is initiated on the light strand from promoter LSP (Light Strand
Promoter) that leads to the generation of short transcripts that act as primers in DNA replication,
as well as a polycistronic mRNA that encodes the ND6 protein, a component of Complex I, and
multiple tRNAs (20). Processing of these transcribed messages is proposed to take place via the
tRNA punctuation model. This model suggests that tRNA secondary structures, within
polycistronic mRNAs, act as molecular punctuation marks to signal for endonucleolytic cleavage
before and after the tRNA messages where the protein-coding genes reside (57).
Mitochondrial gene transcription is regulated by genes encoded in the nucleus which give
rise to the mitochondrial RNA polymerase (POLRMT), mitochondrial transcription factors B1,
B2 and A (TFB1M, TFB2M and TFAM respectively) and mitochondrial termination factor
(mTERF). These factors work together to initiate transcription in a site-specific and species73

specific manner. Much work remains to determine how these proteins interact exactly with the
mitochondrial genome. One study aimed at uncovering the role of mTERF, found that this
protein can initiate and terminate transcription of the rRNA transcript by binding the DNA at
both the HSP1 promoter and at the end of the 16S rRNA gene causing a looping out effect of the
rRNA genes, and allowing for the recycling of the transcription apparatus.
A single mitochondrion in a human cell contains, on average, five mitochondrial
genomes while each cell can contain anywhere from 100 to 1000 mitochondria (64), with
cultured human cells containing an estimated 8000 mtDNA genomes (13). These mitochondrial
genomes allow for a more fine-tuned response to environmental stimuli outside and within the
cell and make it possible to respond very rapidly to stimuli such as growth and division where
energy requirements are high. Packaging of multiple genomes in the mitochondria is achieved by
the TFAM transcription factor, as well as mtSSB and Twinkle helicase (22), proteins necessary
for mitochondrial DNA replication which occurs independently of nuclear DNA replication. This
packaging produces small structures called nucleoids which are tethered to the mitochondrial
inner membrane and act in much the same way as histones do for nuclear DNA as TFAM is
integral to mitochondrial DNA transcription and replication (19).
The research presented in this thesis was carried out to determine if the production of the
oncometabolite, 2-HG, had an effect on mitochondrial function via an altered epigenetic pattern.
Effective transcription of the mitochondrial genome through proper epigenetic modifications
could possibly be necessary to carry out metabolic processes in the cell and transcription of the
mitochondrial genome will be studied in future experiments to determine if this is the case. In
this thesis, we have proposed a novel function of 2-HG in affecting the 5-hydroxymethylcytosine
levels of the mitochondria which may lead to altered mitochondrial gene transcription impairing
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cellular metabolism. This work will assist in determining the function of 5hydroxymethylcytosine in the mitochondria and determine how the level of this modification
affects mitochondrial gene transcription and metabolic function.
Discovery of a novel oncogene: Isocitrate Dehydrogenase
In an effort to determine genetic alterations in glioblastoma, one of the most aggressive
and most common brain cancers in humans, DNA sequencing has been employed to determine
which genes of the genome become mutated and act as tumor suppressors or oncogenes. At the
time, one gene of interest that became mutated recurred over and over again in multiple tumor
samples, the gene that encodes the Isocitrate Dehydrogenase 1 enzyme, a key enzyme of the
TCA cycle. The most commonly found mutation of IDH1 was found to affect an arginine residue
in the active site of the enzyme (59). In fact, almost all of the grade II/III gliomas as well as
many secondary glioblastomas contained a mutation in the active site of the IDH1 enzyme, the
enzyme that locates to the cytoplasm and peroxisomes of the cell. This mutation of IDH1, which
converts the molecule isocitrate into α-ketoglutarate, a metabolite necessary for many cellular
processes, was found to be heterozygous, with retention of a wild type allele, and therefore
proposed to be autosomal dominant. This mutation was originally thought to result in a buildup
of precursor molecules in the cell much the same way as the loss of function mutations found in
the Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) enzymes. FH and SDH occur
in a single allele in the germline and tumors show a loss of heterozygosity with loss of
expression of the remaining allele, producing tumors functionally null in these enzymes (89).
When mutated, these enzymes lead to a buildup of precursor molecules, fumarate and succinate,
which stabilize the HIF-1α protein and promote angiogenesis. These enzymes are also proposed
to be inhibitory to α-ketoglutarate enzymes as well. IDH2, the mitochondrial isoform of this
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enzyme, was also found to be mutated in many brain cancers as well in acute myeloid leukemia.
Of particular interest is the fact that IDH1 and IDH2 mutations have been shown to be mutually
exclusive of each other and do not occur simultaneously in the same sample leading many to
propose these mutations have a similar function (21). They are also mutually exclusive to TET2
mutations. When analyzed, these IDH mutations were found to be heterozygous and retain a
wild-type allele while the other is mutated. To date, no IDH mutations have been reported to be
homozygous. This heterozygous nature has prompted many to speculate that these IDH enzymes
may act as oncogenes and that these mutations result in a novel gain of function. This
speculation was supported when levels of a metabolite, 2-hydroxyglutarate, were found to be
dramatically increased in glioblastoma cells in vitro when mutant IDH1 was expressed (15).
In normal human cells, the concentration of 2-HG in the cell is maintained at an
extremely low level around 0.1nM. This molecule is a by-product of a transhydrogenase reaction
and is usually converted to α-ketoglutarate fairly quickly by 2-hydroxyglutarate dehydrogenase,
a nuclear encoded protein. When these 2-HGDH enzymes become mutated, 2-HG builds up in
the cell and results in a disease termed 2-hydroxyglutaric aciduria which can lead to mental
retardation, leukoencephalopathy, and a decline in psychomotor skills. In IDH mutant patients,
the levels of 2-HG in serum can rise from 0.1nM to between 1 and 30mM (17) and the (D)isoform of this metabolite is solely produced which is typical of most enzymatic reactions.
Experiments using the (L)-isoform of this metabolite have shown that it is actually a stronger
inhibitor of α-ketoglutarate dependent enzymes than the (D)-isoform and is more potent in
disrupting histone demethylases’ as well as TET enzymes’ normal functions (86).
When 2-hydroxyglutarate is allowed to build up in the cell, the oncometabolite
competitively inhibits the enzymes that utilize α-ketoglutarate to function much in the same way
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that the buildup of fumarate and succinate can lead to decreased enzymatic activity of these
enzymes. Production of 2-HG by mutant metabolic enzymes such as IDH, can also lead to
reduced levels of α-ketoglutarate as this molecule is a common analog of the necessary
metabolite. To date, more than 70 different enzymes utilize α-ketoglutarate as a substrate. These
enzymes include prolyl hydroxylases, histone modifying enzymes, as well as DNA
methylcytosine dioxygenases and other α-ketoglutarate dependent enzymes which can have a
profound effect on gene expression. The activity of prolyl hydroxylases was inhibited following
the introduction of IDH2 mutations in cell culture models leading to greater stability of their
target molecule, HIF-1α. Consequently, when IDH2 is mutated, stem/progenitor cell marks (Ckit) increase while markers indicative of mature hematopoietic cells (Gr-1 and Mac-1) became
reduced in the cell indicating a profound effect on cellular differentiation by the competitive
inhibition of these enzymes by 2-hydroxyglutarate (21). Mutant IDH enzymes also impair
histone demethylation in a 2-HG dependent manner and have increased levels of repressive
histone modifications such as H3K9me3 leading to a block in cellular differentiation (49).
Inhibition of DNA-modifying enzymes also occurs when 2-hydroxyglutarate is elevated in the
cell. Of these enzymes, the Ten-eleven Translocation (TET) proteins are integral members
which catalyze the conversion of 5-methylcytosine residues in the nuclear genome to 5hydroxymethylcytosine (72). This novel cytosine modification has been thought to be integral to
the DNA demethylation pathway as it can further oxidize modified cytosine residues to 5formylcytosine and 5-carboxylcytosine. Utilizing AID deamination and the base excision repair
pathway, this carboxyl modification can be converted to an unmodified cytosine base.
The TET family of enzymes, of which there are three members, utilize Fe2+, O2 and αketoglutarate to catalyze the conversion of 5mC to 5hmC and can subsequently continue to
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oxidize the 5hmC modified base to 5-formylcytosine and finally 5-carboxylcytosine which can
then be deaminated to thymine and removed via the base excision repair machinery of the cell
(32, 26). This active DNA demethylation pathway has been proposed as a way of removing the
methylation marks on cytosine residues of transcriptionally repressed promoters and may
therefore lead to the re-expression of silenced genes. As the TET enzymes require αketoglutarate, it has been proven that a surplus of 2-hydroxyglutarate can competitively inhibit
these enzymes, as well as possibly reduce the pool of α-ketoglutarate available within the cell,
leading to a decline in the amount of 5-hydroxymethylcytosine residues present in the nuclear
genome and a consequent rise in the abundance of genomic 5-methylcytosine. This results in the
establishment of the CpG island hypermethylator phenotype (CIMP) in these IDH mutant
samples (21, 76).
Other effects of (D)-2-hydroxyglutarate production by mutated IDH proteins have been
determined to affect other aspects of the cell. When IDH1 is mutated, studies have shown that
collagen maturation is impaired due to inhibition of collagen proline-hydroxylases which also
may act as tumor suppressors in B-cell lymphomas. DNA repair enzymes also seem to be
affected by 2-HG as well as RNA demethylases that regulate cellular metabolism.
The predicted role of mutant IDH in human mitochondria
Recently, the Taylor lab identified the presence of the DNMT1 maintenance
methyltransferase in the mitochondria, translocated using a mitochondrial targeting sequence
(MTS) encoded from an upstream start codon. The presence of a MTS was conserved among
mammalian species, and was shown to translocate a heterologous protein (GFP) into the
mitochondria. This finding helped to solidify the fact that cytosine modifications can exist in the
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mitochondria as well as in the nucleus in the context of CpG sites in the mitochondrial genome
by a mitochondrial isoform of DNMT, mtDNMT1. Interestingly, this mtDNMT1 isoform is upregulated by PGC1α and NRF1, necessary molecules for the oxidative stress response and for
mitochondrial biogenesis (65, 84), and down-regulated by p53, a tumor suppressor gene mutated
in over 50% of all human tumors. Loss of p53 function in cells leads to a modest 3-fold increase
in total DNMT1 transcript but a 6-fold increase in the abundance of mtDNMT1 gene transcript.
Through the use of the MeDIP technique as well as the β-glucosyltransferase assay used to
detect 5-hydroxymethylcytosine in DNA, it was determined that 5-hydroxymethylcytosine, as
well as 5-methylcytosine residues are present in the mitochondrial genome (68). Furthermore,
increased expression of mtDNMT1 resulted in a gene-and-strand specific alteration in
mitochondrial transcription. The conservation of the enzymes and modifications resulting from
their action within mitochondria has led to the hypothesis that mitochondrial gene transcription
might be regulated through epigenetic mechanisms.
With this information, the research described in this thesis was undertaken to determine
whether mutant IDH1, IDH2 or both isoforms have any effect on the patterns of methylation and
hydroxymethylation found in the human mitochondrial genome. As is shown in Chapter 3, when
either the IDH1 or IDH2 mutant enzymes are transfected into human cell lines, a phenomenon
similar to that seen in the nucleus is found in regards to hydroxymethylation most likely through
the inhibition of TET enzymes by 2-hydroxyglutarate. After 48 hours, we show that expression
of mutant IDH1 or IDH2 causes a substantial decline in the level of 5-hydroxymethylcytosine to
about 40-50% that of the wild-type IDH transfected samples. For the experiments performed in
this thesis, both the 12S and 16S rRNA gene regions were first analyzed to determine if mutant
IDH affects levels of modified cytosine residues in the mitochondria. This effect is most notable
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within the 12S ribosomal RNA region of the mitochondrial genome, but less apparent in the 16S
rRNA region of the genome where levels of 5hmC may remain unchanged or even increase in
the presence of IDH mutations. Future studies investigating the other mitochondrial genes will be
performed to see if a similar trend is produced across the entire mitochondrial genome after
mutant IDH is expressed. It is possible to infer that when IDH1 or IDH2 are mutated in human
cell cultures, the levels of 2-hydroxyglutarate produced by these mutations rise above their
normal cellular levels and competitively inhibit the TET enzymes as the experiments performed
in this thesis were done exactly the same as those reported earlier (86, 21). This inhibition in the
active site of the enzyme results in fewer 5-hydroxymethylcytosine residues converted from
existing 5-methylcytosine residues in the mitochondrial genome. Impressively, these levels of
5hmC are reduced fairly quickly, after only 48 hours post-transfection, with mutant IDH,
showing that the effects of IDH mutants can be felt in the mitochondrial genome extremely
rapidly and suggesting that the stores of α-ketoglutarate are under tight control within the cell.
Also of interest is that when these mutant IDH isoforms are co-transfected with the D-isoform of
2-hydroxyglutarate dehydrogenase (2-HGDH), the levels of 5hmC begin to rise back to the
levels seen in IDH wild-type transfected samples showing that this enzyme can relieve the
inhibition on the TET enzymes by the 2-HG oncometabolite, presumably through conversion of
2-HG to α-KG. While rescue is clearly observed in the IDH1 transfected samples, the levels of
5hmC found in the IDH2 mutant transfected samples tend to decrease when co-transfected with
the D-2HGDH enzyme. To accurately determine how this enzyme affects 2-HG levels, mass
spectrometry should be employed to measure the level of this oncometabolite after cotransfection of (D)-2HGDH. As α-ketoglutarate is not as limited in the mitochondria as it is in
the nucleus, the level of 2-HG produced by this mutation could be substantially larger than that
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produced by the IDH1 mutant enzyme and should be measured using mass spectrometry to
accurately determine the levels of this metabolite in the cell. In fact, reports have demonstrated
that the concentration of 2-HG is much higher in IDH2 mutated samples than IDH1 mutant
samples which may possibly be saturating the 2-HGDH enzyme which can travel between the
mitochondria and cytoplasm.
While the effects of IDH mutation on 5hmC content in the mitochondrial genome can be
determined fairly easily, how IDH1 and IDH2 mutant enzymes affect the levels of 5methylcytosine in the rRNA regions of the genome is less clear. As a result of the decrease in
5hmC seen in these transiently transfected cells, we expected to see a concomitant increase in
5mC. As can be seen from the results in Chapter 3, when IDH1 mutant enzymes are introduced
into HEK293 cells, the level of 5-methylcytosine in these samples increases in both the 12S and
16S regions of the genome. However, in the IDH1 and IDH2 wild-type samples, the levels of
5mC are well below the 5mC levels of their respective IgG mouse control levels which is used as
a measure of baseline. When analyzing the IDH2 R172K mutation, the levels of 5mC, as a
measure of percentage of input, in both the 12S and 16S region decrease below the IgG mouse
control which is opposite to the effect this mutation has on the nuclear genome. There are several
technical factors that could contribute to the inconclusive nature of these results. The
performance of the mouse IgG control antibody shows a very high degree of batch-to-batch
variability. We have tested two different lots of mouse IgG. The first lot consistently gave
backgrounds that were substantially above 5mC antibody signal. The control IgG used in the
experiments described in this thesis was somewhat better in performance, but still gave higher
background than those previously reported (68). Others have reported that alterations in nuclear
5mC, as a result of transfection with IDH mutants, occur slowly over many cell generations (76).
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We have accordingly isolated clones of stably transfected cells expressing varying levels of
mutant IDH proteins to determine whether a similar phenomenon occurs in the mitochondrial
genome. Co-transfection of the IDH1 mutation with the D-2HGDH enzyme leads to a decrease
in the levels of 5mC content when analyzing the 12S and 16S rRNA regions, while cotransfection of the IDH2 mutant enzyme leads to an increase in 5mC content. With this
confounding evidence, it is difficult to determine how IDH mutations affect the 5-methylcytosine
levels of the mitochondrial genome. Recently, a positive correlation has been determined
between mutant IDH1 and p53 expression as lower grade gliomas, which typically harbor the
IDH1 R132H mutation, also show an increase in p53 levels which is a commonly mutated
protein found in cancers (7, 73). This interaction seems to provide evidence that mitochondria
are integral to cell cycle progression (40) although the functional significance of this interaction
remains to be determined. With the evidence produced by the Taylor lab regarding the effects of
p53 on mtDNMT1 transcription, it is probable that a connection exists between mutant IDH and
mtDNMT1 expression. Future studies will determine how mutant IDH affects the expression
level of mtDNMT1 to find if a connection truly exists between this oncogene and the
methylation machinery of the mitochodnria.
To better understand how and if the mitochondrial rRNA regions become
hypermethylated, stable clones were produced that express either the wild-type or mutant
enzymes of the IDH isoforms. In the nuclear genome, it was determined that hypermethylation of
both cytosine residues and histone markers does occur slowly over many cell generations when
mutant IDH is introduced (about 20 passages of HEK293 cells) (49). How these IDH mutations
may come to affect the mitochondrial genome over time remains to be determined and we are
currently working to solve this question. Stable clones have been produced and analyzed using
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immunoblotting techniques. As was shown in Chapter 3, the clones chosen express their
transfected mutant IDH protein at a level equivalent to or similar to the endogenous levels of
IDH in HEK293 cells when using an antibody specific for IDH proteins. We have also chosen
clones that overexpress mutant IDH to varying degrees. Future MeDIPs and hydroxy-MeDIPs
will be performed at different passages of the cells to determine if the levels of 5-methylcytosine
rise substantially above baseline in the mitochondrial genome or whether a different effect is
seen in regards to mitochondrial cytosine modifications when IDH mutant proteins are expressed
stably within the cell population.
The Importance of Mitochondrial Cytosine Modifications
It has been shown that not only is TET2 present in the mitochondria but also the
enzymatic machinery necessary for the base excision repair pathway indicating a role for 5hydroxymethylcytosine in DNA demethylation and gene re-expression in the mitochondria that
is similar to that found in the nucleus. Also, as mitochondria contain protein-containing nucleoid
structures that package the DNA with the high-mobility group protein TFAM and other proteins,
methylation and hydroxymethylation may be integral in the stability of these higher order
structures and therefore help to control transcription of mitochondrial genes. What’s more, this
control could be specific to certain mitochondrial genes as changes in gene transcription occur
differentially in different areas of the genome as a result of changes in mtDNMT1 levels (68).
These results point toward mitochondrial cytosine modifications as a possible biomarker and
diagnostic tool for disease (30).
Studies have determined that Complexes IV and V can also be inhibited by the
oncometabolite, 2-HG, and lead to superoxide production and decreased cell viability (43). It is
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possible that this inhibition is caused by methylation of the genes encoding proteins necessary
for these complexes although further work remains to be done. The effect IDH1 and IDH2
mutations have on the 12S rRNA region of the mitochondrial genome is intriguing. Methylation
of this area has been implicated in disease and ageing phenotypes. One epidemiological study
determined that when workers were exposed to airborne pollutants, methylation levels of the 12S
rRNA region increased compared to subjects not exposed to these same pollutants (Byun, 2013).
Another study measured the level of 12S methylation in adult males and found that the
percentage of methylation in this region decreased with age (Giordano, 2012). While this work
remains to be replicated, it is interesting that methylation of this region may play such an
important role in human health and could possibly become a target of therapeutics. By
comparison, work regarding how methylation of the 16S rRNA region of the mitochondrial
genome, which is downstream of the 12S region, has been lacking and will require future
experiments to determine if modification of this rRNA gene is significant to overall
mitochondrial function.
Just as important as methylation status and cellular differentiation, mutation of IDH
enzymes could affect cellular metabolism as well. When mutated, the defective allele of IDH
utilizes α-ketoglutarate and NADPH to produce 2-hydroxyglutarate. This results in a net
reduction of available NADPH in the cell decreasing the NADPH/NADP+ ratio (Bleeker, 2010).
This molecule, which functions as an electron acceptor for the oxidative phosphorylation
pathway, is vital to macromolecular biosynthesis and serves as a powerful antioxidant (37).
Many anabolic pathways employ NADPH as a co-factor in the synthesis of nucleic acids, protein
and lipids (10). As mentioned previously, NADPH serves as a co-factor for glutathione reductase
to clear the cell of harmful free radicals. Dysregulation of the cellular redox status can contribute
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to cellular transformation and tumorigenesis. Although how this redox status is affected in IDHmutant tumors remains to be determined, studies suggest IDH provides a protective role (8, 44).
Perspectives and Conclusions
The effects of IDH mutations in the cell are multifaceted. This novel oncogene serves to
dysregulate both cellular gene expression and differentiation. The involvement of mutant IDH
and the oncometabolite produced in cellular metabolism is of considerable interest and is the
focus of work arising from this thesis. Cell culture work has determined that this enzyme, when
mutated, leads to an increase in a metabolite, (D)-2-HG, which competitively inhibits enzymes
that utilize α-ketoglutarate in the cell, the metabolite normally produced by IDH (86). This leads
to increased gene methylation over time via inhibition of TET proteins in the nucleus (76, 21). In
this thesis, we determined the effect of this oncometabolite on the mitochondrial genome, in
which cytosine residues have been shown to be both methylated and hydroxymethylated. The
results obtained clearly show an effect of 2-HG on hydroxymethylation of specific mitochondrial
genes. Further work will need to be done to determine how this mutated enzyme affects
methylation levels and how these different methylation patterns affect mitochondrial function
and mitochondrial gene transcription. As described by Nass, methylation in the mitochondria is
quite sparse and tightly regulated (54). Also, how NADPH reduction affects cellular metabolism
will be vital to understanding this enzyme’s function. To determine the functional consequences
of decreasing 5hmC levels, abundance of mitochondrial transcripts will be analyzed to determine
if this modification has an effect on gene expression in this subcellular compartment. Also, the
new XF Analyzer technology developed by Seahorse Bioscience could be utilized to measure
mitochondrial function in individual cells by determining oxygen consumption and extracellular
acidification as a function of respiration and glycolysis respectively. If IDH mutations affect
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gene expression through decreased hydroxymethylation in the mitochondrial genome as well as
decreasing NADPH stores in this organelle, we would expect that respiration might be less
effective in cells harboring this mutation. This may thus push cells towards a more glycolytic
state thereby increasing the amount of lactate produced by the cell since ATP will not be
produced as rapidly as needed.
The mitochondrial genome accounts for less than 1% of the total DNA found in human
cells. However, the information encoded on this genome is integral to the health and viability of
human cells. While it remains unclear how epigenetic markers affect the mitochondrial genome,
it is interesting to speculate about the role of both 5-methylcytosine and 5hydroxymethylcytosine in both mitochondrial maintenance and transcription. Our work suggests
an important interplay between epigenetics and the metabolism of the human cell. Dr. Warburg’s
work, published more than half a century ago, has taken on a new importance as our
understanding of the relationship between misregulated metabolism and carcinogenesis expands.
With the work performed in this thesis, we have expanded our understanding of epigenetic
factors in the mitochondria and opened the way to a greater understanding of the impact of
aberrant metabolic enzymes on the mitochondrion and the cell. A new area of research into
mitochondrial epigenetics has been opened linking metabolism and cytosine modification
together via the mutation of the isocitrate dehydrogenase gene.
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